

47<sup>th</sup> Annual Report  
2024-2025



**#CACHET/REBOOT**

**United We Rise!**  
**One Team, One Goal**

**₹ 1000 Crores**



**CACHET**

A Subsidiary of :



**ALKEM LABORATORIES LTD.**

**COMPANY INFORMATION****BOARD OF DIRECTORS:**

Mr. Satish Kumar Singh	:	Managing Director
Mrs. Premlata Singh	:	Non-Executive Director
Mr. Arunkumar D. Deshmukh	:	Non-Executive Independent Director
Mrs. (Dr.) Anuja M. Sinha	:	Non-Executive Independent Director

**AUDIT COMMITTEE:**

Mr. Arunkumar D. Deshmukh	:	Chairman
Mrs. (Dr.) Anuja M. Sinha	:	Member
Mr. Satish Kumar Singh	:	Member

**NOMINATION AND REMUNERATION COMMITTEE:**

Mr. Arunkumar D. Deshmukh	:	Chairman
Mrs. (Dr.) Anuja M. Sinha	:	Member
Mrs. Premlata Singh	:	Member

**CORPORATE SOCIAL RESPONSIBILITY (CSR) COMMITTEE:**

Mr. Arunkumar D. Deshmukh	:	Chairman
Mrs. (Dr.) Anuja M. Sinha	:	Member
Mr. Satish Kumar Singh	:	Member

<b>REGISTERED OFFICE:</b> Exhibition Road, P.S.-Gandhi Maidan, Patna-800001, Bihar.	<b>HEAD OFFICE:</b> 415, Shah Nahar, Dr. E. Moses Road, Worli, Mumbai, Maharashtra-400018.
<b>BANKERS:</b> Saraswat Co-Op Bank Ltd. Axis Bank Ltd. HDFC Bank Ltd. Bank of Baroda State Bank of India ICICI Bank Ltd. Punjab National Bank	<b>REGISTRAR AND SHARE TRANSFER AGENT:</b> Link Intime India Pvt. Ltd., C 101, 247 Park, L.B.S.Marg, Vikhroli (West), Mumbai - 400083. Tel. No.: 022 - 4918 6270, Fax No.: 022 - 4918 6060 Toll-free No.: 1800 1020 878.
<b>STATUTORY AUDITORS:</b> M/s. R. S. Sanghai & Associates, Chartered Accountants.	<b>COST AUDITOR:</b> Mr. Suresh D. Shenoy, Cost Accountant.
<b>SECRETARIAL AUDITORS:</b> M/s. DM & Associates Company Secretaries LLP, Practicing Company Secretaries	<b>INTERNAL AUDITORS:</b> M/s. Kaushal Kumar & Co., Chartered Accountants M/s. KKC LLP., Chartered Accountants.

**47<sup>th</sup> ANNUAL GENERAL MEETING:**

Day, Date & Time	: Friday, 25 <sup>th</sup> day of July, 2025 at 3.00 p.m.
Venue	: C/o. Alkem House, Exhibition Road, P.S.-Gandhi Maidan, Patna-800001, Bihar.



**CACHET PHARMACEUTICALS PRIVATE LIMITED**

CIN - U24230BR1978PTC001328

Regd. Off.: C/o. Alkem House, Exhibition Road,

P. S. Gandhi Maidan, Patna – 800001, Bihar.

Tel. Nos. – 0612-2322570/ 2322588.

Email: legal@cachetindia.com

**NOTICE**

**NOTICE** is hereby given that the 47<sup>th</sup> Annual General Meeting of the members of **CACHET PHARMACEUTICALS PRIVATE LIMITED** will be held on Friday, the 25<sup>th</sup> day of July, 2025 at 3.00 p.m. at the Registered Office of the Company at C/o. Alkem House, Exhibition Road, P. S. Gandhi Maidan, Patna - 800 001, Bihar to transact the following business:

**ORDINARY BUSINESS:**

1. To receive, consider and adopt the Audited Financial Statements with notes thereon of the Company for the financial year ended on 31<sup>st</sup> March, 2025 and the reports of the Board of Directors and the Auditors thereon.
2. To appoint a director in place of Mr. Satish Kumar Singh (DIN:00245703), who retires by rotation and being eligible, offers himself for re-appointment.

**SPECIAL BUSINESS:**

3. To consider and if thought fit to pass with or without modifications the following resolution as an Ordinary Resolution:-

**"RESOLVED THAT** pursuant to the provisions of Section 139(8) of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (The Rules), including any statutory modification(s) thereof for the time being in force and pursuant to recommendation made by the Board of Directors at its meeting held on 30<sup>th</sup> June, 2025, **M/s. GMJ & Co., Chartered Accountants, (Firm Registration No. 103429W )**, be and is hereby appointed as statutory auditor of the company for the financial year 2025-2026 to 2029-2030, to fill casual vacancy caused by resignation of **M/s. R. S. Sanghai & Associates, Chartered Accountants (Firm Reg. No.109094W).**"

**"RESOLVED FURTHER THAT** M/s. GMJ & Co., Chartered Accountants, (Firm Registration No.103429W), be and is hereby appointed as statutory auditor of the company for the financial years 2025-2026 to 2029-2030, from the conclusion of this 47<sup>th</sup> Annual General Meeting to till the conclusion of 52<sup>nd</sup> Annual General Meeting of the company and that they shall conduct the statutory audit for the period ended 2025-2026 to 2029-2030, on such remuneration as may be fixed by the Board of Directors in consultation with them."

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and are hereby authorized to settle any question, difficulty or doubt, that may arise and to file the relevant forms, documents and returns with the office of the Registrar of Companies as per the applicable Provisions of the Companies Act, 2013 and to do all acts, deeds and things as may be deemed necessary to give effect to the above resolution."





**4. To consider and if thought fit to pass with or without modifications the following resolution as an Ordinary Resolution:-**

**"RESOLVED THAT** pursuant to the provisions of Section 148(3) of the Companies Act, 2013 and read with Rule 14(a) of the Companies (Audit and Auditors) Rules, 2014 and other applicable provisions, if any, of the Companies Act, 2013, payment of Remuneration of Rs.300,000/- (Rupees Three Lakhs only) plus out of pocket expenses and applicable taxes to Mr. Suresh D. Shenoy, Cost Accountants (Membership No. 8318) for conducting the cost audit of cost records made and maintained by the company pertaining to pharmaceuticals product for the year ending March 31, 2026 be and is hereby determined".

**RESOLVED FURTHER THAT** the Board of Directors of the Company (which includes a Committee, constituted for the time being in force) be and is hereby authorized to do all such acts, deeds and things, to enter into such agreement(s), deed(s) of amendment(s) or any such document(s), as the Board may, in its absolute discretion, consider necessary, expedient or desirable including power to sub-delegate, in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit."

**By Order of the Board,  
For CACHET PHARMACEUTICALS PVT. LTD.**



**Satish Kumar Singh  
Managing Director  
DIN:00245703**



Place: Mumbai  
Dated: 30/06/2025

\*\*\*\*\*





**NOTES: -**

1. An Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 relating to Special Business to be transacted at the Annual General Meeting is annexed hereto.
2. A member entitled to attend and vote is also entitled to appoint a proxy to attend and, on a poll, to vote instead of himself/herself. Such proxy need not be a member of the company. Proxies in order to be valid and effective must be delivered at the registered office of the company not later than forty-eight hours before the commencement of the meeting.
3. Corporate members intending to send their authorized representative is requested to send a duly certified copy of the board resolution authorizing their representatives to attend.
4. Members are requested to notify immediately, change in their address, if any, to the Company quoting their Folio Numbers.
5. Members are requested to send their queries, if any, on the financial accounts at least 7 days in advance so that the information can be made available at the meeting.
6. Members who have not applied for Dematerialization of shares are requested to apply for Demat the shares applying to Depository Participant (DP) (with CDSL connectivity) with the ISIN of the Company i.e. INE0EQ801018.
7. All documents referred to in the Notice will be available for inspection at the Company's registered office between 11:00 am and 1:00 pm upto 23<sup>rd</sup> July, 2024 on all days (except Saturdays, Sundays and public holidays).

**EXPLANATORY STATEMENT IN RESPECT OF THE SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013:**

**Item No. 3:**

M/s. R. S. Sanghai & Associates, Chartered Accountants (Firm Reg. No.109094W) have tendered their resignation as Statutory Auditors w.e.f. 09/06/2025 informing that they are unable to continue as auditors of the company due personal / professional reasons, this has resulted into a casual vacancy in the office of Statutory Auditors of the Company as envisaged by Section 139(8) of the Companies Act, 2013. Casual vacancy caused by the resignation of an auditor shall be approved by the shareholders in the General Meeting within three months from the date of recommendation of the Board of Directors of the Company. The Board of Directors of the Company recommended through the resolution passed on 30/06/2025, the appointment of M/s. GMJ & Co., Chartered Accountants, (Firm Registration No.103429W) as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/s. R. S. Sanghai & Associates. Accordingly, Shareholders' approval by way of Ordinary resolution is sought. M/s. GMJ & Co., Chartered Accountants, (Firm Registration No. 103429W), have conveyed their consent for being appointed as the Statutory Auditors of the Company along with a confirmation that, their appointment, if made by the members, would be within the limits prescribed under the Companies Act, 2013 and shall satisfy the criteria as provided under section 141 of the Companies Act, 2013. The Board of Directors of the Company recommends the passing of the resolution in Item No. 03 of the notice as an ordinary resolution.

None of the Directors or Key Managerial Persons of the Company (including their relatives), except to the extent of their shareholding in the Company, are concerned or interested in the said resolution.

**Item No.4:**

The Board of Directors of the Company at their meeting held on 23<sup>rd</sup> May, 2025 appointed Mr. Suresh D. Shenoy, Cost Accountant (Membership No. 8318) as the cost auditor of the company for the Financial Year 2025-2026. As per Rule





14 of Companies (Audit and Auditors) Rules 2014, the appointment of and the remuneration payable to the Cost Auditor requires approval of Shareholders and hence this resolution is put for the consideration of the shareholders.

None of the Directors of the Company and their relatives are concerned or interested, whether financially or otherwise, in the Resolution.

Your directors recommend the passing of the resolution listed at item no.4.

**By Order of the Board,**

**For CACHET PHARMACEUTICALS PVT. LTD.**

Satish Kumar Singh  
Managing Director  
DIN:00245703



Place: Mumbai  
Dated: 30/06/2025

\*\*\*\*\*

**CACHET PHARMACEUTICALS PRIVATE LIMITED**

Regd. Off.: Exhibition Road, P.S.-Gandhi Maidan, Patna – 800001. CIN - U24230BR1978PTC001328,  
Tel. No. – 0612-2322570/ 2322588, [www.cachetindia.com](http://www.cachetindia.com)

**ATTENDANCE SLIP**

(To be presented at the entrance)

47<sup>th</sup> Annual General Meeting of the Members of **Cachet Pharmaceuticals Private Limited** on Friday, July 25, 2025 at 3:00 P.M. at the Registered Office of the Company at Exhibition Road, P.S.-Gandhi Maidan, Patna-800001.

Folio No. \_\_\_\_\_

DP ID No. \_\_\_\_\_

Client ID No. \_\_\_\_\_

Name of the Member: \_\_\_\_\_

Signature: \_\_\_\_\_

Name of the Proxyholder: \_\_\_\_\_

Signature: \_\_\_\_\_

1. Only Member/Proxyholder can attend the Meeting.
2. Member/Proxyholder should bring his/her copy of the AGM Notice for reference at the Meeting.

**CACHET PHARMACEUTICALS PRIVATE LIMITED**

Regd. Off.: Exhibition Road, P.S.-Gandhi Maidan, Patna – 800001. CIN - U24230BR1978PTC001328,  
Tel. No. – 0612-2322570/ 2322588, [www.cachetindia.com](http://www.cachetindia.com)

**PROXY FORM**

(Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014)

47<sup>th</sup> Annual General Meeting of the Members of **Cachet Pharmaceuticals Private Limited** on Friday, July 25, 2025 at 3:00 P.M. at the Registered Office of the Company at Exhibition Road, P. S.- Gandhi Maidan, Patna-800001.

Name of the Member(s) : \_\_\_\_\_

Registered address: \_\_\_\_\_ E-mail ID : \_\_\_\_\_

Folio No./Client ID No.: \_\_\_\_\_ DP ID No.: \_\_\_\_\_

I/We, being the member(s) holding \_\_\_\_\_ of Shares of Cachet Pharmaceuticals Private Limited, hereby appoint:

1. Name: \_\_\_\_\_ E-mail Id: \_\_\_\_\_  
Address: \_\_\_\_\_ Signature: \_\_\_\_\_  
or failing him
2. Name: \_\_\_\_\_ E-mail Id: \_\_\_\_\_  
Address: \_\_\_\_\_ Signature: \_\_\_\_\_  
or failing him
3. Name: \_\_\_\_\_ E-mail Id: \_\_\_\_\_  
Address: \_\_\_\_\_ Signature: \_\_\_\_\_

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 47<sup>th</sup> Annual General Meeting of the Members of **Cachet Pharmaceuticals Private Limited** to be held on Friday, July 25, 2025 at 3:00 P.M. at the Registered Office of the Company at C/o. Alkem House, Exhibition Road, P.S.-Gandhi Maidan, Patna-800001 and at any adjournment thereof in respect of Ordinary / Special Resolutions as indicated below:

1. Adoption of the Audited Financial Statements with notes thereon for the financial year ended 31<sup>st</sup> March, 2025, the Reports of the Board of Directors' and Auditors' thereon.
2. Re- appointment of Mr. Satish Kumar Singh, Director who is retiring by rotation.
3. Appointment of M/s. GMJ & Co. Chartered Accountants as a Statutory Auditor in place of M/s. R. S. Sanghai & Associates, Chartered Accountants for a term of five years.
4. Determination of Remuneration of Cost Auditor.

Signed \_\_\_\_\_ day of \_\_\_\_\_ 2025

Signature of Shareholder \_\_\_\_\_


Signature of Proxy holder(s) \_\_\_\_\_

Affix  
Revenue  
stamp of  
Rs.1/-

**NOTES:** This Form of Proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company at Exhibition Road, P.S.-Gandhi Maidan, Patna – 800001, not less than 48 hours before the commencement of the Meeting.



## ROUTE MAP TO THE AGM VENUE



**DIRECTOR'S REPORT**

Dear Shareholders,

Your Board of Directors hereby present the 47<sup>th</sup> Director's Report on the Business, operations and state of affairs of the Company together with audited financial statements of the company for the year ended 31<sup>st</sup> March, 2025.

**FINANCIAL SUMMARY AND HIGHLIGHTS:**

(Rs. In Lakhs)

Particulars	Financial Year 2024-2025	Financial Year 2023-2024
<b>Revenue from Operations (Gross)</b>	45,936.04	44,243.63
Add: Other Income	1,865.69	664.06
<b>Total Income</b>	<b>47,801.73</b>	<b>44,907.69</b>
Operating Results:		
<b>Profit / (Loss) Before Tax</b>	<b>5,895.74</b>	<b>3,031.53</b>
Less : Income Tax	1,671.48	1,186.08
Less : Deferred Tax	22.49	(122.15)
Less: Prior Period Adjustments	(107.78)	1,141.08
<b>Profit After Tax</b>	<b>4,309.55</b>	<b>826.52</b>
<b>Other Equity</b>		
Add: Balance B/F from the previous year	<b>8,274.42</b>	<b>7,488.54</b>
Add.: Retained Earning and Other Comprehensive Income/(Loss)	4,188.27	785.88
<b>Balance Profit/(Loss) C/F to the next year</b>	<b>12,462.69</b>	<b>8,274.42</b>

Your Directors are pleasure to present the financial report for the year ended 31<sup>st</sup> March, 2025. During the year under review, the Company's gross revenue from operations increased by 3.83% to Rs. 45,936.04 Lakhs as compared to the previous year's gross revenue from operations of Rs.44,243.63 Lakhs. Profit after Tax increased by 421.41% to Rs.4309.55 Lakhs compared to previous year's Profit after Tax of Rs.826.52 Lakhs.

**AMOUNTS TRANSFERRED TO RESERVES:**

The Company doesn't propose to transfer any amount to General Reserves account.

**DIVIDEND:**

The directors do not propose to declare any dividend for the year under review.

**SEGMENT-WISE PERFORMANCE:**

The Company is into single reportable segment only.

**INDIAN ACCOUNTING STANDARDS (Ind AS):**

The company has adopted Indian Accounting Standards (Ind AS) as per the notification dated February 16, 2015 issued by the Ministry of Corporate Affairs (MCA). Ind AS has replaced the existing GAAP prescribed under the Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014. The Company has prepared financials using Ind AS for the year ended March 31, 2025.





**CHANGE IN NATURE OF BUSINESS ACTIVITY, IF ANY:**

During the year under review, the company has no changes in its business activities and operations.

**CHANGES IN SHARES CAPITAL:**

No Changes in Share Capital of the company took place during the year under review.

**CREDIT RATING OF SECURITIES**

The Company is a private limited company hence there was no requirement of obtaining credit rating for its securities

**INVESTORS EDUCATION AND PROTECTION FUND (IEPF):**

There were no amounts which were required to be transfer to the Investors Education and Protection Fund.

**MANAGEMENT AND BOARD OF DIRECTORS:**

The Board of Directors have met Six (6) times during the year, from 1<sup>st</sup> April, 2024 to 31<sup>st</sup> March, 2025. The Board meetings were held on the following dates:

24<sup>th</sup> May, 2024, 30<sup>th</sup> July, 2024, 9<sup>th</sup> August, 2024, 26<sup>th</sup> September, 2024, 7<sup>th</sup> November, 2024 and 6<sup>th</sup> February, 2025.

Pursuant to Para VII (1) of Schedule IV to the Companies Act, 2013, Independent Directors (IDs) are required to hold at least one meeting without the attendance of Non-independent directors and members of the management. The separate meeting of IDs were held on 6<sup>th</sup> February, 2024 for the financial year 2024-25 and they were evaluated the performance of the board of directors and committee thereof.

Following are the details of attendance during the year:

Sr. No.	Name of Director	Designation	No. of Meetings Held	Nos. of Meetings attended	Attendance at AGM
1.	Mr. Satish Kumar Singh	Managing Director	6	6	Yes
2.	Mrs. Premlata Singh	Director	6	6	No
3.	Mr. Arunkumar D. Deshmukh	Independent Director	6	6	Yes
4.	Mrs. (Dr.) Anuja M. Sinha	Independent Director	6	6	Yes

Mr. Satish Kumar Singh, Managing Director who is longest in the office since his last appointment shall be liable to retire by rotation and being eligible, offers himself for re-appointment. Accordingly a resolution proposing his candidature for re- appointment forms part of the notice of 47<sup>th</sup> Annual General Meeting.

**Audit Committee:**

The Audit Committee of the company comprised of:

Sr. No.	Name of Director	Designation	Nos. of Audit Committee Meetings attended
1.	Mr. Arunkumar D. Deshmukh	Chairman	5
2.	Mrs.(Dr.)Anuja M. Sinha	Member	5
3.	Mr. Satish Kumar Singh	Member	5





During the year under review Six (5) meetings of the Audit committee were held on 24<sup>th</sup> May, 2024, 9<sup>th</sup> August, 2024, 26<sup>th</sup> September, 2024, 7<sup>th</sup> November, 2024 and 6<sup>th</sup> February, 2025.

#### Nomination & Remuneration Committee (NRC):

The Nomination and Remuneration Committee comprised of:

Sr. No.	Name of Director	Designation	Nos. of NRC Committee Meetings attended
1.	Mr. Arunkumar D. Deshmukh	Chairman	3
2.	Mrs.(Dr.)Anuja M. Sinha	Member	3
3.	Mr. Premlata Singh	Member	3

During the year under review three meetings of the Nomination and Remuneration committee was held on 24<sup>th</sup> May, 2024, 30<sup>th</sup> July, 2024, and 6<sup>th</sup> February, 2025.

The Nomination and Remuneration Policy of the company placed on the company's portal i.e. [www.cachetindia.com](http://www.cachetindia.com) and silent features thereof is attached as **Annexure-3** to the Board Report. The said policy of the Company on directors' appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a Director, and other matters provided under sub-section (3) of Section 178 of the Companies Act, 2013, adopted by the Board. Further the remuneration paid to the Directors is as per the terms laid out in the Nomination and Remuneration Policy of the Company.

#### Corporate Social Responsibility (CSR) Committee:

The Corporate Social Responsibility Committee of the company comprised of:

Sr. No.	Name of Director	Designation	Nos. of CSR Committee Meetings attended
1.	Mr. Arunkumar D. Deshmukh	Chairman	1
2.	Mrs.(Dr.)Anuja M. Sinha	Member	1
3.	Mr. Satish Kumar Singh	Member	1

During the year under review one meeting by of the Corporate Social Responsibility committee was held on 6<sup>th</sup> February, 2025.

#### Formal Annual Board Evaluation:

In compliance with the Companies Act, 2013, during the year, the Board adopted a formal mechanism for evaluating its performance as well as that of its Committees and Individual Directors including the Chairman of the Board. Structured questionnaires were used in the overall Board evaluation comprising various aspects of Board functions. The evaluation of Independent Directors was carried out by the entire Board and that of the Chairman and Non-Independent Directors were carried out by the Independent Directors. The Directors were satisfied with the evaluation results, which reflected the overall engagement of the Board and its Committees with the Company.

#### Declaration by Independent Directors:

The Company has received necessary declaration from each independent director under section 149(7) of the Companies Act, 2013, that he / she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013.



#### Internal financial controls and their adequacy:

The Board has adopted policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to the company's policies, the safeguarding of its assets, the prevention and detection of fraud and error, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial disclosures. The Company has an adequate internal controls system commensurate with its size and the nature of its business. All the transactions entered into by the Company are duly authorized and recorded correctly. All operating parameters are monitored and controlled. The top management and the Audit Committee of the Board of Directors review the adequacy and effectiveness of internal control systems from time to time.

#### DISCLOSURES RELATING TO HOLDING COMPANY, SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES:

Pursuant to Section 2(87) of the Companies Act, 2013, the company is subsidiary company of M/s. Alkem Laboratories Limited by holding 60.63% of total shares capital of the company and which listed on Bombay Stock Exchange and National Stock Exchange. The Company doesn't have any subsidiary company.

By virtue of being subsidiary M/s. Alkem Laboratories Limited; the following are the fellow subsidiaries of the company which are subsidiaries of Holding company:

Name	Country
<b>DOMESTIC</b>	
Indchemie Health Specialities Private Limited	India
Alkem Foundation	India
Connect 2 Clinic Private Limited	India
Alkem Medetch Private Limited (Wholly Owned Subsidiary)	India
Enzene Biosciences Limited	India
Alixer Nexgen Therapeutics Limited #	India
Alkem Wellness Limited *	India
<b>INTERNATIONAL</b>	
Ascend Laboratories (Pty) Limited	South Africa
Ascend GmbH	Germany
Alkem Laboratories Corporation	Philippines
Pharmacor Pty Limited	Australia
S & B Holdings S.a.r.l.	Luxembourg
The Pharma Network, LLC (Wholly owned subsidiary of S&B Holdings B.V)	United States of America
Ascend Laboratories, LLC (Wholly owned by The Pharma Network, LLC)	United States of America
S&B Pharma LLC (Wholly owned by The Pharma Network, LLC)	United States of America
Ascend Laboratories SDN BHD.	Malaysia
Ascend Laboratories SpA	Chile
Pharma Network SpA (Wholly owned by Ascend Laboratories SpA)	Chile
Ascend Laboratories S.A de C.V. (Wholly owned by Ascend Laboratories SpA)	Mexico
Pharmacor Ltd.	Kenya
The Pharma Network LLP	Kazakhstan
Ascend Laboratories (UK) Ltd.	United Kingdom







Ascend Laboratories Ltd.	Canada
Ascend Laboratories SAS	Colombia
Alkem Laboratories Korea, Inc	Korea
Enzene Inc. (Wholly Owned by Enzene Biosciences Limited)	United States of America
Pharmacor Limited (Wholly Owned by Pharmacor Pty Limited)	New Zealand
Pharmacor SpA @	Chile

# Incorporated on 12th July, 2024

\* Incorporated on 16th September, 2024

@ Wholly owned subsidiary of Pharmacor Pty Limited, Australia

#### PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

Particulars and details of loans given, investments made or guarantees given and securities provided, if any, are given in the Notes to the Financial Statements.

#### PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES REFERRED TO IN SEC. 188(1):

As per requirement of the Companies Act, 2013, all related party transactions were as per omnibus approval of the Audit Committee and Board.

Following material related party transactions i.e. transaction exceeding 10% of the annual turnover as per the audited financial statement, were entered during the year by the company, however the same were at arm's length and in ordinary course of business were:

Name of the Related Party	Nature of Relationship	Duration of Contract	Salient terms	Amt. (Rs. In Lakhs)
<b>Sale of Finished Goods:</b>				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	15,236.48

Disclosures of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of the Section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto are enclosed with this report in Form AOC-2 as **Annexure-2**.

#### CORPORATE SOCIAL RESPONSIBILITY (CSR):

The provisions of Section 135 of the Companies Act, 2013 were applicable for the F.Y. 2024-25. The Board of Directors of the Company having CSR Policy in accordance with Schedule VII of the Companies Act, 2013. The company constituted the Corporate Social Responsibility Committee of the Board of Director and same mentioned at the beginning of this report. Relevant disclosure of CSR disclosed on the company's portal i.e. [www.cachetindia.com](http://www.cachetindia.com).

Enclosed herewith as **Annexure 7** the Annual Report for the F.Y. 31<sup>st</sup> March, 2025 on Corporate Social Responsibility Pursuant to Companies (Corporate Social Responsibility Policy) Rules, 2014.

#### CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information relating to conservation of energy, technology absorption, foreign exchange earnings and outgo pursuant to the provisions of Section 134(3)(m) of the Companies Act, 2013 is given in the **Annexure-6** forming part of this report.





**RISK MANAGEMENT:**

At Cachet, risk management activities are part of the operational responsibilities of the management and has made them a significant part of overall governance. The Company implemented risk management policy for a broad and strategic approach to risk management, taking into consideration both internal and external risks to respond promptly to changing dynamics.

**VIGIL MECHANISAM / WHISTLE BLOWER POLICY:**

Pursuant to sub-section (9) of section 177 read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, the Vigil Mechanism / Whistle Blower policy shall not be applicable to the company. The Company has framed and implemented WhistleBlower Policy for good governance which helps the organization to raise genuine concern to the Board of Directors and Management of the Company.

**MATERIAL ORDERS OF JUDICIAL BODIES / REGULATORS:**

During the year under review, there were no significant and material orders passed by any regulator, court, tribunal, statutory and quasi-judicial body, impacting the going concern status of the company.

**STATUTORY AUDITOR AND AUDITORS' REPORT:**

Company's Statutory Auditors M/s. R. S. Sanghai & Associates, Chartered Accountants, audited financials of the Company for the financial year 2024-2025. The Auditors' Report for the said financial year does not contain any qualification, reservation or adverse remark and is enclosed with the 47<sup>th</sup> Annual Report of the company. Further there were no instances of fraud reported by the Auditor.

**SECRETARIAL AUDIT REPORT:**

Pursuant to the provisions of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. DM & Associates Company Secretaries LLP, Company Secretaries (Regd. No.L2017MH003500) to conduct the Secretarial Audit of the Company for the financial year 2024-2025. The Secretarial Audit Report is annexed to this Report as **Annexure 1**. The said Report does not contain any adverse any qualification, reservations or remark.

**COST AUDIT AND COST RECORDS:**

Pursuant to the provisions of Section 148 of the Act and the Rules made thereunder, the company is required to maintain cost records as specified by the Central Government and hence as per the recommendation of the Audit Committee, the Board of Directors had appointed Mr. Suresh D. Shenoy, Cost Accountant (Membership No. 8318), as the Cost Auditor of the Company to conduct the audit of the cost records of the Company for the financial year 2024- 2025. The Company has also received a certificate from the Cost Auditor certifying his independence and arm's length relationship with the Company. The Board of Directors propose to appoint the Cost Auditor for the financial year 2025-2026. A resolution for ratification of the remuneration payable to the Cost Auditor for FY 2025-2026 is proposed in the forthcoming AGM for seeking approval of Members. The Cost Audit Report will be filed within the period stipulated under the Act.

**INTERNAL AUDITORS & THEIR REPORT:**

Pursuant to the provisions of Section 138 of the Companies Act, 2013 and Rules made thereunder, the Company had appointed M/s. Kaushal Kumar & Co., Chartered Accountants and M/s. KKC & Associates LLP, Chartered Accountants as Internal Auditors to conduct audit during the financial year 2024-2025.





The internal auditors appointed by the Board act independently and reports given by them are placed before the board from time to time in order to take remedial measures on the adverse comments by them.

**COMPLIANCE WITH SECRETARIAL STANDARDS:**

The company has complied with applicable Secretarial Standards issued by The Institute of Company Secretary of India and other Secretarial standards voluntarily adopted by the company.

**EXTRACT OF ANNUAL RETURN:**

The extract of the Annual Return in Form MGT-9 is enclosed with this report as **Annexure-4** and Annual returns of the Company are disclosed at the company's web portal i.e. [www.cachetindia.com](http://www.cachetindia.com).

**STATEMENT IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROL WITH REFERENCE TO THE FINANCIAL STATEMENTS:**

Pursuant to Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013, the Independent Auditors' of the company have audited company's internal financial controls over financial reporting for the financial year ended on 31<sup>st</sup> March, 2025 and report thereon is enclosed to the Independent Auditors report as "Annexure B".

**DEPOSITS:**

The company has not accepted any deposits from the public falling within the purview of Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 and accordingly no amount was outstanding as on the balance sheet date.

**DIRECTOR'S RESPONSIBILITY STATEMENT:**

Pursuant to Section 134(3)(C) & (5) of the Companies Act, 2013, Directors confirm that:

- (i) In the preparation of the annual accounts, the applicable accounting standards have been followed with no material departures;
- (ii) That the directors have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (iii) That the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (iv) That the directors have prepared the annual accounts on a going concern basis.
- (v) That the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that these are adequate and are operating effectively.

**PARTICULARS OF EMPLOYEES AND REMUNERATION:**

The information required under Section 197(12) of the Companies Act, 2013 read with the Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended, is provided in **Annexure-5** to this report.

**DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:**





The company has formed the committee to prevent Sexual harassment under the Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 and Formulated Policy on prevention of sexual harassment and safety of women employees at workplace. There was no incidence of sexual harassment that took place during the financial year ended 31<sup>st</sup> March, 2025.

**HUMAN RESOURCES:**

The Company treats its "Human Resources" as one of its most important assets. We focus on all aspects of the employee lifecycle. This provides holistic experience for the employees as well. During their tenure at the Company, employees are motivated through various skill development programs. We create effective dialogue through our communication channels to ensure that feedback reaches the relevant team, including leadership.

The Company continuously invests in attraction, retention and development of talent on an on-going basis. A number of programs that provide focused people attention are currently underway. The Company thrust is on the promotion of talent internally through job rotation and job enlargement.


**OTHER:**

No disclosure is required in respect of the details relating to the deposits covered under Chapter V of the Companies Act, 2013, as the Company has not accepted any deposit. There was no significant or material order passed by any regulator or court or tribunal which would impact the status of the Company as a going concern and the operations in future. The Company has complied with the Secretarial Standards issued by the Institute of Company Secretaries of India

**ACKNOWLEDGEMENTS:**

The Board of Directors place on record their earnest appreciation for the unstinted commitment, dedication, hard work and significant contribution made by employees of the company. The Board of directors also sincerely thank all stakeholders, medical professionals, banks and trade associates for their continued assistance, co-operation and support.

By Order of the Board,  
For CACHET PHARMACEUTICALS PVT. LTD.



Satish Kumar Singh  
Managing Director  
DIN NO.:00245703



Arunkumar D. Deshmukh  
Director  
DIN NO.:07210367

Place: Mumbai  
Dated: 23/05/2025

\*\*\*\*\*





Annexure-1: Secretarial Audit Report

**DM & ASSOCIATES COMPANY SECRETARIES LLP**  
(LLPIN NO. AAI-4743)

[Firm Registration No: L2017MH003500] [Peer Review Certificate: 758/2020]  
REGD. OFFICE: # 205, NADIADWALA MARKET, PODDAR ROAD, MALAD (EAST), MUMBAI-400097  
Tel No. 022-28443641 Email: [dmassociatesllp@gmail.com](mailto:dmassociatesllp@gmail.com)

Form no. MR-3

**Secretarial Audit Report**

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

**For the Financial Year Ended March 31, 2025**

To,  
The Members,  
**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
Exhibition Road., P.S.-Gandhi Maidan  
Patna Br 800001

Dear Members,

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Cachet Pharmaceuticals Private Limited** (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the Company has, during the audit period covering the financial year ended March 31, 2025, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2025 according to the provisions of:

1. The Companies Act, 2013 (the Act) and the rules made thereunder;
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder: **NA**;
3. The Depositories Act, 1996 and the Regulations and bye-laws framed thereunder;
4. The provisions of Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial borrowings: **NA**;
5. Provisions of Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') were not applicable to the Company during the Audit Period.

**We report that** we have relied on the compliance certificates issued by its officers and taken on record by the Board of Directors at their meeting(s) for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations to the Company and on examination of the relevant documents and records in pursuance thereof on test-check basis the Company has complied with the laws applicable specifically to the Company as stated below. For Income tax laws and compliance with applicable accounting standards we have relied on the Audit report issued by the Statutory Auditors.

The following are the major head / group of Acts, Laws and Regulations as applicable to the Company:

- i. Food Safety And Standards Act, 2006
- ii. Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954
- iii. Drugs and Cosmetics Act, 1940
- iv. Narcotic Drugs and Psychotropic Substances Act, 1985



- v. The Air (Prevention and Control of Pollution) Act, 1981 and Rules issued by state control Board
- vi. The Water (Prevention and Control of Pollution) Act, 1974 and Rules issued by state control Board
- vii. The Patents Act, 1970
- viii. The Trade Marks Act, 1999
- ix. Indian Boilers Act, 1923
- x. Poisons Act, 1919

We have also examined compliance with the applicable clauses of the Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, rules, regulations, guidelines, standards etc. mentioned above. In a few instances, there were delays in filing certain e-forms with the Registrar of Companies on the MCA portal; however, the Company has regularised the same by filing the requisite forms along with the prescribed additional fees.

**We further report that** the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non - Executive Directors and Independent Directors. There were no changes in the composition of the Board of Directors that took place during the period under review.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting

Majority decision is carried through while there were no dissenting members' views which are to be captured and recorded as part of the minutes.

**We further report that** there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**We further report that** during the audit period, there was no specific action was taken by the Company having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines:

**For DM & Associates Company Secretaries LLP**

**Company Secretaries**

TRIBHUWNEISHWAR  
BHUNWNEISHWAR KAUSHIK

Digitally signed by TRIBHUWNEISHWAR  
BHUNWNEISHWAR KAUSHIK  
Date: 2025.05.01 14:24:48 +05'30'

**Tribhuwneshwar B. Kaushik**

**Partner**

**FCS NO 10607**

**C P NO 16207**

**UDIN: F010607G000246425**

Place : Mumbai

Date : May 01, 2025

**Note:** This report is to be read with our letter of even date that is annexed as Annexure - I and forms an integral part of this report.





## **DM & ASSOCIATES COMPANY SECRETARIES LLP**

**(LLPIN NO. AAI-4743)**

---

[Firm Registration No: L2017MH003500] [Peer Review Certificate: 758/2020]  
REGD. OFFICE: # 205, NADIADWALA MARKET, PODDAR ROAD, MALAD (EAST), MUMBAI-400097  
Tel No. 022-28443641 Email: [dmassociatesllp@gmail.com](mailto:dmassociatesllp@gmail.com)

---

### **ANNEXURE – I**

To  
The Members,  
**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
Exhibition Road., P.S.-Gandhi Maidan  
Patna Br 800001

Our report of even date is to be read along with this letter:

1. Maintenance of secretarial records is the responsibility of management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. Wherever required, we have obtained the Management Representation about the compliance of laws, rules and regulations and happening of events, etc.
5. The compliance of the provisions of corporate and other applicable laws, rules and regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For DM & Associates Company Secretaries LLP**  
**Company Secretaries**

TRIBHUWNESHWAR  
BHUVNESHVAR KAUSHIK

Digitally signed by  
TRIBHUWNESHWAR BHUVNESHVAR  
KAUSHIK  
Date: 2025.05.01 14:25:11 +05'30'

**Tribhawneshwar B. Kaushik**  
**Partner**  
**FCS NO 10607**  
**C P NO 16207**  
**UDIN: F010607G000246425**

Place : Mumbai  
Date : May 01, 2025



## Annexure-2

## Form No. AOC-2

Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto:

Details of contracts or arrangements or transactions not at arm's length basis:

- |   |     |
|---|-----|
| (a) Name(s) of the related party and nature of relationship:                                      | NIL |
| (b) Nature of contracts / arrangements / transactions:  | NIL |
| (c) Duration of the contracts / arrangements / transactions:                                      | NIL |
| (d) Salient terms of the contracts or arrangements or transactions including the value, if any:   | NIL |
| (e) Justification for entering into such contracts or arrangements or transactions:               | NIL |
| (f) Date(s) of approval by the Board:   | NIL |
| (g) Amount paid as advances, if any:  | NIL |
| (h) Date on which the special resolution was passed in general meeting as required under Sec.188: | NIL |

1. Details of material contracts or arrangement or transactions at arm's length basis:

Name of the Related party	Nature of relationship	Duration of Contract	Salient terms	Amount (Rs. In Lakhs)
<b>Nature of Contract:</b>				
<b>Remuneration to Related Party</b>				
Mr. Sanjay Kumar	Relative of Director	As per terms of appointment	As per terms of appointment	119.73
			<b>Total</b>	<b>119.73</b>
<b>Sale of Finished Goods &amp; Consumables:</b>				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	15,236.48
			<b>Total</b>	<b>15,236.48</b>
<b>Purchase of Raw and Packing Material :</b>				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	0.31
Galpha Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	0.29
			<b>Total</b>	<b>0.60</b>
<b>Purchase of Finished Goods:</b>				
Indchemie Health Specialities Pvt. Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	744.23
Galpha Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	111.61
			<b>Total</b>	<b>855.84</b>







Manufacturing Charges received:				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	649.08
			<b>Total</b>	<b>649.08</b>
Rent Paid:				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	49.21
			<b>Total</b>	<b>49.21</b>
Reimbursement of Expenses:				
Indchemie Health Specialities Pvt. Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	1.88
			<b>Total</b>	<b>1.88</b>
Royalty Income:				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	3.17
			<b>Total</b>	<b>3.17</b>
Recovery of Expenses:				
Alkem Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	50.19
Galpha Laboratories Ltd.	Related Party	Ongoing Agreement	Based on Transfer Pricing Guidelines	1.48
			<b>Total</b>	<b>51.67</b>

Note: Appropriate approvals have been taken for related party transactions. Advances have been adjusted against billing, wherever applicable.

\*\*\*\*\*



## Annexure-3

**SALIENT FEATURES OF NOMINATION AND REMUNERATION POLICY**

This Nomination and Remuneration Policy is being formulated by **M/s. Cachet Pharmaceuticals Private Limited ('the Company')** in compliance with Section 178 of the Companies Act, 2013 as amended from time to time. This policy on nomination and remuneration of Directors, Key Managerial Personnel and Senior Management has been formulated by the Nomination and Remuneration Committee (NRC or the Committee) and has been approved by the Board of Directors of the Company.

**SALIENT FEATURES :**

The Nomination and Remuneration Policy:

- Formulates criteria for determining qualifications, positive attributes and independence of a director.
- Formulate criteria for evaluation of Independent Directors and the Board.
- Identify persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down in this policy.
- Carry out evaluation of Director's performance.
- Recommend to the Board the appointment and removal of Directors and Senior Management.
- Recommend to the Board policy relating to remuneration for Directors, Key Managerial Personnel and Senior Management.
- Devise a policy on Board diversity, composition, size.
- Succession planning for replacing Key Executives and overseeing.
- Carry out any other function as is mandated by the Board from time to time and / or enforced by any statutory notification, amendment or modification, as may be applicable.
- Perform such other functions as may be necessary or appropriate for the performance of its duties.

\*\*\*\*\*







## Annexure-4

**FORM NO. MGT 9**  
**EXTRACT OF ANNUAL RETURN**  
**As on financial year ended on 31.03.2025**

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.

**I. REGISTRATION & OTHER DETAILS:**

1	CIN	U24230BR1978PTC001328
2	Registration Date	25.04.1978
3	Name of the Company	Cachet Pharmaceuticals Private Limited
4	Category/Sub-category of the Company	Company Limited by Shares Indian Non-Government Company
5	Address of the Registered office & contact Details	Exhibition Road, P.S. Gandhi Maidan, Patna - 800 001, Ph.- 0612-2322570, 2322588
6	Whether listed company	No
7	Name, Address & contact details of the Registrar & Transfer Agent, if any.	Link Intime India Pvt. Ltd, C 101, 247 Park, L.B.S.Marg, Vikhroli (West), Mumbai - 400083. Tel. No.: 022 - 4918 6270 Fax No.: 022 - 4918 6060 Toll-free No.: 1800 1020 878.

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:**

(All the business activities contributing 10 % or more of the total turnover of the company shall be stated)			
SR. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	Pharmaceutical and Nutraceutical Products	21002 & 21003	100

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:**

SR. NO.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1.	M/s Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai- 400013.	U00305MH1973P LC174201	Holding	60.63%	2(46)



**IV. SHARE HOLDING PATTERN:**

(Equity share capital breakup as percentage of total equity)

**(I) Category-wise Share Holding**

Category of Shareholders	No. of Shares held at the beginning of the year [As on 31-March-2024]				No. of Shares held at the end of the year [As on 31-March-2025]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
<b>A. Promoters</b>									
(1) Indian									
a) Individual/ HUF	3638	3383	7,021	39.37%	3638	3383	7,021	39.37%	0.00%
b) Central Govt.	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) State Govt.(s)	-	-	-	0.00%	-	-	-	0.00%	0.00%
d) Bodies Corp.	10,813	-	10,813	60.63%	10,813	-	10,813	60.63%	0.00%
e) Banks / FI	-	-	-	0.00%	-	-	-	0.00%	0.00%
f) Any other	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub Total (A) (1)</b>	<b>14,451</b>	<b>3,383</b>	<b>17,834</b>	<b>100%</b>	<b>14,451</b>	<b>3,383</b>	<b>17,834</b>	<b>100%</b>	<b>0.00%</b>
(2) Foreign									
a) NRI Individuals	-	-	-	0.00%	-	-	-	0.00%	0.00%
b) Other Individuals	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) Bodies Corp.	-	-	-	0.00%	-	-	-	0.00%	0.00%
d) Any other	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub Total (A) (2)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0.00%</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0.00%</b>	<b>0.00%</b>
<b>TOTAL (A)</b>	<b>14,451</b>	<b>3,383</b>	<b>17,834</b>	<b>100%</b>	<b>14,451</b>	<b>3,383</b>	<b>17,834</b>	<b>100%</b>	<b>0.00%</b>
<b>B. Public Shareholding</b>									
<b>1. Institutions</b>									
a) Mutual Funds	-	-	-	0.00%	-	-	-	0.00%	0.00%
b) Banks / FI	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) Central Govt.	-	-	-	0.00%	-	-	-	0.00%	0.00%
d) State Govt.(s)	-	-	-	0.00%	-	-	-	0.00%	0.00%
e) Venture Capital Funds	-	-	-	0.00%	-	-	-	0.00%	0.00%







f) Insurance Companies	-	-	-	0.00%	-	-	-	0.00%	0.00%
g) FIIs	-	-	-	0.00%	-	-	-	0.00%	0.00%
h) Foreign Venture Capital Funds	-	-	-	0.00%	-	-	-	0.00%	0.00%
i) Others (specify)	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub-total (B)(1):-</b>	-	-	-	<b>0.00%</b>	-	-	-	<b>0.00%</b>	<b>0.00%</b>
<b>2. Non-Institutions</b>									
a) Bodies Corp.									
i) Indian	-	-	-	0.00%	-	-	-	0.00%	0.00%
ii) Overseas	-	-	-	0.00%	-	-	-	0.00%	0.00%
b) Individuals	-	-			-	-			
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	-	-	-	0.00%	-	-	-	0.00%	0.00%
ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) Others (specify)	-	-	-	-	-	-	-	-	-
Non Resident Indians	-	-	-	0.00%	-	-	-	0.00%	0.00%
Overseas Corporate Bodies	-	-	-	0.00%	-	-	-	0.00%	0.00%
Foreign Nationals	-	-	-	0.00%	-	-	-	0.00%	0.00%
Clearing Members	-	-	-	0.00%	-	-	-	0.00%	0.00%
Trusts	-	-	-	0.00%	-	-	-	0.00%	0.00%
Foreign Bodies – D R	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub-total (B)(2):-</b>	-	-	-	<b>0.00%</b>	-	-	-	<b>0.00%</b>	<b>0.00%</b>
<b>Total Public (B)</b>	-	-	-	<b>0.00%</b>	-	-	-	<b>0.00%</b>	<b>0.00%</b>
<b>C. Shares held by Custodian for GDRs &amp; ADRs</b>	-	-	-	<b>0.00%</b>	-	-	-	<b>0.00%</b>	<b>0.00%</b>
<b>Grand Total (A+B+C)</b>	<b>14,451</b>	<b>3,383</b>	<b>17,834</b>	<b>100%</b>	<b>14,451</b>	<b>3,383</b>	<b>17,834</b>	<b>100%</b>	<b>0.00%</b>



## (ii) Shareholding of Promoter :

Sr. No.	Shareholder's Name	Shareholding at the beginning of the year [as on 31 <sup>st</sup> March, 2024]			Shareholding at the end of the year [as on 31 <sup>st</sup> March, 2025]			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged/ encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	M/s Alkem Laboratories Ltd.	10,813	60.63%	--	10,813	60.63%	--	0.00%
2.	Ms. Prerana Kumar	758	4.25%	--	758	4.25%	--	0.00%
3.	Mr. Basudeo Narain Singh	731	4.10%	--	731	4.10%	--	0.00%
4.	Ms. Anita Singh	585	3.28%	--	585	3.28%	--	0.00%
5.	Mr. Dhananjay Kumar Singh	525	2.94%	--	525	2.94%	--	0.00%
6.	Mr. Mritunjay Kumar Singh	525	2.94%	--	525	2.94%	--	0.00%
7.	Mr. Satish Kumar Singh	797	4.47%	--	797	4.47%	--	0.00%
8.	Ms. Manju Singh	428	2.40%	--	428	2.40%	--	0.00%
9.	Ms. Madhurima Singh	365	2.05%	--	365	2.05%	--	0.00%
10.	Ms. Seema Singh	365	2.05%	--	365	2.05%	--	0.00%
11.	Mr. Sarvesh Singh	340	1.91%	--	340	1.91%	--	0.00%
12.	Mr. Sandeep Singh	340	1.91%	--	340	1.91%	--	0.00%
13.	Ms. Jayanti Sinha	233	1.31%	--	233	1.31%	--	0.00%
14.	Mr. Rajesh Kumar	225	1.26%	--	225	1.26%	--	0.00%
15.	Mr. Balmiki Prasad Singh	504	2.83%	--	504	2.83%	--	0.00%
16.	Ms. Archana Singh	150	0.84%	--	150	0.84%	--	0.00%
17.	Mr. Rajeev Ranjan	150	0.84%	--	150	0.84%	--	0.00%
	<b>Total</b>	<b>17,834</b>	<b>100%</b>	<b>--</b>	<b>17,834</b>	<b>100%</b>	<b>--</b>	<b>0.00%</b>

Change in Promoters' Shareholding (please specify, if there is no change):

Sr. No.	Name of the Shareholder	Shareholding at the beginning of the year		Shareholding at the end of the year		Change	Date	Reason
		No. of Shares	% of total Shares	No. of Shares	% of total Shares			
1								





**(iii) Shareholding Pattern of top ten Shareholders:**
*(Other than Directors, Promoters and Holders of GDRs and ADRs):*

S.N.	For each of the Top 10 shareholders	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	Name						
	At the beginning of the year						
	Changes during the year						
	At the end of the year						
2	Name						
	At the beginning of the year						
	Changes during the year						
	At the end of the year						

**(iv) Shareholding of Directors and Key Managerial Personnel:**

Sr. No.	Shareholding of each Directors and each Key Managerial Personnel	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1.	Mr. Satish Kumar Singh						
	At the beginning of the year			797	4.47%	797	4.47%
	Changes during the year			--	0.00%	--	0%
	At the end of the year			797	4.47%	797	4.47%

**V. INDEBTEDNESS:**

Indebtedness of the Company including interest outstanding/accrued but not due for payment:

(Rs. In

Lakhs)

Particulars	Secured Loans excluding Deposits	Unsecured Loans	Deposits	Total Indebtedness
<b>Indebtedness at the beginning of the financial year:</b>				
i) Principal Amount	134.45	-	-	134.45
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>134.45</b>	<b>-</b>	<b>-</b>	<b>134.45</b>
<b>Change in Indebtedness during the financial year:</b>				
Addition	530.36	-	-	530.36





Reduction	664.81	-	-	664.81
Changes in CC limit	-	-	-	-
<b>Net Change</b>	<b>-134.45</b>	-	-	<b>-134.45</b>
<b>Indebtedness at the end of the financial year:</b>				
i) Principal Amount	0	-	-	0
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>0</b>	-	-	<b>0</b>

**VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:****A. Remuneration to Managing Director, Whole-time Directors and/or Manager:**

Sr. No.	Particulars of Remuneration	Name of MD/WTG/ Manager	Total Amount
	<b>Name &amp; Designation</b>	--	-
1	Gross salary	-	NIL
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	NIL	
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	
2	Stock Option / Sweat Equity	-	-
3	Commission - as % of profit	-	-
4	Others, please specify	-	-
	<b>Total (A)</b>	<b>NIL</b>	<b>NIL</b>
	<b>Ceiling as per the Act</b>	<b>NIL</b>	<b>NIL</b>





**B. Remuneration to other Directors: (Rs. In Lakhs)**

S.N.	Particulars of Remuneration	Name of Directors		Total Amount
1	Independent Directors	Mr. Arunkumar Deshmukh	Mrs. (Dr.) Anuja M. Sinha	
	Fee for attending board committee	1.05	0.75	1.80
	Commission	-	-	-
	Others, please specify	-	-	-
	Total (1)	1.05	0.75	1.80
2	Other Non-Executive Directors	-	-	-
	Fee for attending board committee	-	-	-
	Commission	-	-	-
	Others, please specify	-	-	-
	Total (2)	-	-	-
	Total (B)=(1+2)	1.05	0.75	1.80
	Total Managerial Remuneration	-	-	1.80

**C. Remuneration to Key Managerial Personnel other than MD/Manager/WTD:**

Sr.N.	Particulars of Remuneration	Name of KMP		Total Amount	
		CEO	CFO	CS	
1	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-	-
2	Stock Option / Sweat Equity	-	-	-	-
3	Commission as % of profit	-	-	-	-
4	Others, please specify	-	-	-	-
	Total	-	-	-	-

**VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:**

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
<b>COMPANY / DIRECTORS / OTHER OFFICERS IN DEFAULT</b>					
Penalty			None		
Punishment			None		
Compounding			None		



**Annexure-5**

Information as per Section 197(12) of the Companies Act, 2013 read with the Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and forming part of the Board's Report for the year ended March 31, 2025.

**A. Employed throughout the year and were in receipt of remuneration for the year which in aggregate was not less than Rs.1.02 Cr. per annum:**

Sr. No.	Name of the Employee	Designation	Remuneration Received (Rs. In Lakhs)	Nature of employment	Age (Yrs)	% of Equity shares held	Whether relative of any director or Manager
1.	RAJEEV RANJAN	PRESIDENT	191.73	Full time	58	0.84%	No
2.	RAJESH KUMAR	CHIEF OPERATING OFFICER	191.73	Full time	56	1.26%	No
3.	SHASHI SHEKHAR KUMAR	PRESIDENT - INTERNATIONAL BUSINESS	126.87	Full time	53	NIL	No
4.	SANJAY KUMAR	PRESIDENT – FACTORY OPERATIONS	119.73	Full time	55	NIL	Yes
5.	JITENDRA KUMAR JHA	CHIEF FINANCE OFFICER	86.59	Full time	44	NIL	No
6.	PRADIPTA KUMAR SAHOO	PRESIDENT-FACTORY OPERATIONS	80.50	Full time	53	NIL	No
7.	SANTOSH KUMAR SINGH	GM - MARKETING	59.00	Full time	46	NIL	No
8.	NIRUPAM BISHWAS	GM- SALES	49.42	Full time	43	Nil	No
9.	RAKESH SABARWAL	GM-SALES	40.95	Full time	57	NIL	No
10.	KRISHNANAND M MISHRA	DGM-MARKETING SUPPORT	38.21	Full time	54	NIL	No

**B. Employed for a part of the year and were in receipt of remuneration which, in the aggregate, was not less than Rs.8.50 Lakhs per month: N.A.**

Sr. No.	Name of the Employee	Designation	Remuneration Received during a part of the year (Rs. In Lakhs)	Nature of employment	Age (Yrs)	% of Equity shares held	Whether relative of any director or Manager
1.	VIMAL WAHI	VP- SALES AND MARKETING	18.18	Full time	56	0.00%	No





**Annexure-6****CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:****A. CONSERVATION OF ENERGY:****a) Energy Conservation Measures taken:**

Energy Conservation continues to receive priority within the Company. The continuous monitoring of the energy consumptions across the Company's locations, has resulted in improvement in maintenance systems and reduction in distribution losses.

i) Specific Energy Conservation measures are already taken to include installation of energy efficient system in the existing equipment, configuration and also capacitors are put on all heavy machines to control the power factor, installation of chiller VSD basis, installation of new transformer as per IS-1180 (PART-I): EEL-2 (2014) Now As EEL-1 (2022).

ii) Maintaining power factor close to 1 to avoiding the penalty.

b) Additional activities, if any: As above

c) Impact of measures taken:

Energy conservation measures of the type mentioned above have resulted in gradual savings in energy.

**Water:-**

Necessary measures already have been taken to save water wastage i.e.

- i. Installed Automatic water system with controlling.
- ii. Reverse osmosis (R.O.) water system rejection (30%) is used in toilets to save water wastage. It is about 3 kilo litre per day.
- iii. Installed sensors in water tanks to control the water wastage.
- iv. Rain harvesting pits to save rainwater.

**B. RESEARCH & DEVELOPMENT AND TECHNOLOGY ABSORPTION: RESEARCH & DEVELOPMENT (R & D):****1. Specific areas in which R&D is carried out by the Company:**

Development of formulations for solid dosage tablet and capsules form as immediate release, delayed release, Gastro Resistant release, Chewable tablet, dry powder, Oral liquid like syrup, suspension, oral solution, and various platform technologies.

R & D has developed the formulations for new and existing molecules and drug combinations which include its standardization and execution at production site, evaluation of these batches against reference samples for safety, efficacy and bio-equivalence.

Development of new analytical test procedures for various dosage forms to establish the quality and setting up specification for the release, stability testing of dosage forms as per ICH guidelines to set the shelf life of product & active pharmaceutical ingredient.



## 2. Benefits derived as a result of the above R & D:

Product Improvement, Process Development, Standardization of Quality product Formulation.

## 3. Future plan of action:

- Nutraceuticals product development.
- Technology advancement.
- Development of formulations for Semi regulatory market.
- Development of formulations for Domestic market.

## 4. Expenditure on R & D:

i)	Capital	: Nil
ii)	Recurring	: Nil
iii)	Total	: Nil
iv)	Total R & D Expenditure as percentage to total turnover	: Nil

## DISCLOSURE OF PARTICULARS WITH REGARD TO TECHNOLOGY ABSORPTION:

During the financial year 2024-25, the Company undertook several strategic initiatives to enhance operational efficiency, workforce engagement, and digital integration. Key measures include:

### Implementation of New HR Software Platform:

A comprehensive Human Resources Management System (HRMS) was onboarded to streamline and digitize core HR functions. Key modules, including Onboarding, Attendance, and Core HR, went live successfully during the year. Other modules such as Payroll, Expense Management, Helpdesk, Asset Management, and Employee Engagement are currently in the implementation phase. This system enhances employee lifecycle management and operational transparency.

### Deployment of a New SFA (Sales Force Automation) Module

A new SFA module was rolled out for the field force, catering to both domestic and international business units. The solution includes functionalities such as Standard Tour Planning (STP), Daily Call Reporting (DCR), Expense Management, and E-Detailing.

As part of the eDetailing initiative, the Company has also made the decision to provide tablets to all field staff, including Country Managers, to enhance digital engagement with doctors and ensure consistent, high-quality presentations.

### Data Warehouse Implementation

### EDI – Electronic Data Interchange – Bridging Systems, Safeguarding Data, Empowering Efficiency!

The Company initiated the development of a data warehouse to support Electronic Data Interchange (EDI) with both internal and external systems. This initiative enhances interoperability, enables automated data exchange, and ensures secure, structured information flow across platforms.

In addition, both the HR and SFA platforms have been seamlessly integrated with the existing ERP system, enabling real-time data synchronization and significantly improving cross-departmental decision-making. ADFS-Based Single Sign-On (SSO) Integration

To streamline access and improve security across multiple enterprise applications, Active Directory Federation Services (ADFS) was configured to enable Single Sign-On (SSO) using SAML functionality. This initiative eliminates the need for employees to remember multiple passwords, offering a seamless and secure login experience across integrated third-party software platforms. System Integration for Real-Time Data Visibility







#### **Revamp of Company Website**

The corporate website was completely renovated and relaunched with enhanced design, user experience, and functionality. The new site aligns with the company's branding and digital outreach strategies.

#### **Centralized Storage with NAS Technology**

The Company implemented a Network Attached Storage (NAS) solution to enable centralized data management across multiple office locations. This initiative was achieved without any additional capital expenditure, utilizing existing infrastructure efficiently. The NAS deployment has simplified data access, improved collaboration, and strengthened data security and backup consistency across the organization.

#### **Cybersecurity Enhancement through DNS Traffic Filtering**

To safeguard the organization from internal and external threats, Traplox and Honeytrap security devices were deployed to monitor and filter DNS traffic. These tools restrict unauthorized access to suspicious websites and unknown URLs. In the event of any detected anomalies, these systems automatically initiate protective actions to secure the company network from potential threats.

#### **Employee Empowerment through Virtual Cybersecurity Awareness Training**

To promote a culture of cybersecurity and reduce human-related risks, virtual cybersecurity awareness training sessions were conducted location-wise across the organization. These interactive sessions educated employees on safe digital practices, phishing awareness, and data protection policies, thereby strengthening the first line of defense in the Company's cybersecurity framework.

#### **Biometric Access Control System Implementation**

To strengthen physical security, biometric-based access control systems were installed in all corporate offices. This ensures that only authorized personnel can access office premises, effectively preventing unauthorized entry.

#### **C: FOREIGN EXCHANGE EARNINGS AND OUTGO:**

During the year under review the foreign exchange earnings were Rs.7014.13 Lakhs and outgo was Rs.462.30 Lakhs.

\*\*\*\*\*





## Annexure – 7

**Annual Report for the F.Y. 31<sup>st</sup> March, 2025 on Corporate Social Responsibility**  
(Pursuant to Companies (Corporate Social Responsibility Policy) Rules, 2014)**1. A brief outline of the company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs:**

The provisions of Section 135 of the Companies Act, 2013 were applicable for the F.Y. 2024-25. Hence the Board of Directors of the Company formulated CSR Policy in accordance with Schedule VII of the Companies Act, 2013. The company constituted the Corporate Social Responsibility Committee of the Board of Director in F.Y 2022-23 and same mentioned at the beginning of this report. Relevant disclosure of CSR disclosed on the company's portal i.e. [www.cachetindia.com](http://www.cachetindia.com).

Annual Report for the F.Y. 31<sup>st</sup> March, 2025 on Corporate Social Responsibility Pursuant to Companies (Corporate Social Responsibility Policy) Rules, 2014:

- The Company plans to support/ partner and assist various CSR activities in the following areas:
  - a. To Promote education
  - b. Health Care
  - c. Animal welfare
  - d. Making available safe drinking water
  - e. Transfer to Prime Minister's National Relief Fund

**2. The Composition of the CSR Committee as on March 31, 2025:**

The Corporate Social Responsibility Committee of the company comprised of:

Sr. No.	Name of Director	Designation	Nos. of CSR Committee Meetings attended
1.	Mr. Arunkumar D. Deshmukh	Chairman	1
2.	Mrs. (Dr.) Anuja M. Sinha	Member	1
3.	Mr. Satish Kumar Singh	Member	1

During the year under review one meeting by of the Corporate Social Responsibility committee was held on 6<sup>th</sup> February, 2025.

3. Average net profit of the company for last three financial years: Rs. 2,332.53 Lakhs
4. Prescribed CSR Expenditure:  
(two percent of the amount as in item 3 above) Rs. 46.65 Lakhs
5. Details of CSR spent during the financial year.
- (a) Total amount to be spent for the financial year: Rs. 46.65 Lakhs
- (b) Amount unspent, if any: Rs. NIL
- (c) Manner in which the amount spent during the financial year: As tabled below







1	2	3	4	5	6	7	8
Sr. No	CSR Project or activity identified	Sector in which the project is covered	Projects or Programmes 1) Local area or other 2) Specify the state and district where projects or programs was undertaken	Amount outlay (budget) project or program wise	Amount spent on the projects or programs Sub-heads: 1) Direct Expenditures on projects or programs 2) Overheads	Cumulative Expenditure up to the reporting period.	Amount spent: Direct or through implementing agency
1.	Prime Minister's National Relief Fund	Fund specified as per Schedule VII	Fund specified as per Schedule VII	INR 46.00 Lakhs	INR 46.00 Lakhs	INR 46.00 Lakhs	Direct
2.	Making available safe drinking water	As per Schedule VII	Activity as per Schedule VII	INR 0.65 Lakhs	INR 0.65 Lakhs	INR 0.65 Lakhs	Direct

In case the company has failed to spend the two per cent, of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board report:

N.A.

6. The CSR Committee confirms that the implementation and monitoring of the CSR activities of the Company are in compliance with the CSR objectives and CSR Policy of the Company.

Date: 23/05/2025  
Place: Mumbai



For and on behalf of the Board of Directors  
CACHET PHARMACEUTICALS PRIVATE LIMITED

  
Satish Kumar Singh  
Managing Director  
DIN:00245703

## INDEPENDENT AUDITOR'S REPORT

To the Members of CACHET PHARMACEUTICALS PRIVATE LIMITED

### Report on the Audit of the Financial Statements

#### Opinion

We have audited the accompanying Ind AS financial statements of **CACHET PHARMACEUTICALS PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at 31<sup>st</sup> March, 2025, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity, the Statement of Cash Flows for the year ended on that date and notes to the financial statements, including a summary of material accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March, 2025, and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

#### Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ("SA's") specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

#### Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Management and Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the



Director's Report including Annexures to Director's Report and Company's Information but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

The Company's Management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 (Ind AS) of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management and Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs





will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.
- Conclude on the appropriateness of Management's and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.





We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, based on our audit, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
  - d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act.
  - e) On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2025 and taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2025 from being appointed as a director in terms of Section 164(2) of the Act.
  - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
  - g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
  - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:



- i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements. – Refer Note 3.31 to the financial statements.
- ii. The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. (a) The Management has represented that, to the best of its knowledge and belief, as disclosed in the Note 3.43 to the financial statements, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;  
  
(b) The Management has represented, that, to the best of its knowledge and belief, as disclosed in the Note 3.43 to the financial statements, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;  
  
(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. The company has not declared or paid any dividend during the year.





- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2025 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

For **R.S. SANGHAI & ASSOCIATES**  
**Chartered Accountants**

Firm's registration number: 109094W



A handwritten signature in blue ink, appearing to read "R.S. Sanghai", written over a horizontal line.

**R.S. SANGHAI**

Partner

Place: Mumbai

Date: 23<sup>rd</sup> May, 2025

M. No.: 036931

UDIN No.	2	5	0	3	6	9	3	1	B	M	G	J	D	G	2	0	9	7
----------	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

**Re: CACHET PHARMACEUTICALS PRIVATE LIMITED**

**"Annexure A" to the Independent Auditors' Report for the year ended 31<sup>st</sup> March, 2025**

Referred to in paragraph 1 under the heading 'Report on Other Legal & Regulatory Requirement', of our report of even date to the Ind AS financial statements of the Company for the year ended 31<sup>st</sup> March, 2025, we report that:

- i. In respect of the Company's property, plant and equipment, right-of-use assets and intangible assets:
  - (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment and relevant details of right of use assets.  
  
(B) The Company has maintained proper records showing full particulars of Intangible Assets.
  - (b) The Property, Plant and Equipment have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were physically verified by the management during the year and no material discrepancies were noticed on such verification.
  - (c) Based on our examination of the property tax receipts and lease agreement for land on which building is constructed, registered sale deed / transfer deed / conveyance deed provided to us, we report that, the title in respect of self-constructed buildings and title deeds of all other immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee), disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.
  - (d) The Company has not revalued any of its Property, Plant and Equipment (including right-of-use assets) and intangible assets during the year and accordingly, requirements of para 3(i)(d) is not applicable and hence not commented upon.
  - (e) According to the information and explanations given to us and on the basis of our audit procedures, we report that no proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder against the Company.
- ii. (a) According to the information and explanations given to us and on the basis of our audit procedures, we report that the management has conducted physical verification of inventory at reasonable intervals during the year which in our opinion is appropriate considering the size and the nature of business of the Company. The discrepancies noticed on such physical verification of inventory as compared to book records which has been properly dealt with in the books of account were not more than ten percent in aggregate for each class of inventory.





- (b) The Company has not been sanctioned working capital limits in excess of five crore rupees in aggregate at any point of time during the year from banks or financial institutions on the basis of security of current assets. Hence, reporting requirement under para 3(ii)(b) of the order is not applicable.
- iii. According to the information and explanation given to us and on the basis of our examination of the records of the Company, the Company has not made investments in, provided any guarantee or security, or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnership or any other parties, except for unsecured loans granted to its employees, during the year, in respect of which:
- a) The Company has not given any loan or advance in the nature of loans to any other entity during the year, and hence, reporting requirement under para 3(iii)(a) of the Order is not applicable.
  - b) In our opinion, the investments made and the terms and conditions of the grant of loans to employees, during the year are, prima facie, not prejudicial to the Company's interest.
  - c) In respect of loans granted by the Company to its employees, the schedule of repayment of principal and payment of interest has been stipulated and the repayments of principal amounts and receipts of interest are generally been regular as per stipulation.
  - d) In respect of loans granted by the Company to its employees, there is no overdue amount remaining outstanding as at the balance sheet date.
  - e) No loan granted by the Company which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same employees.
  - f) The Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment during the year. Hence, reporting requirement under para 3(iii)(f) of the order is not applicable.

The Company has not made investments in Firms and Limited Liability Partnerships during the year. Further the Company has not provided any guarantee or security or granted any advances in the nature of loans, secured or unsecured, to Companies, Firms, Limited Liability Partnerships or any other parties.

- iv. In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made, guarantees, and securities provided, as applicable.
- v. The Company has not accepted any deposit in the nature of deposit and amounts which are deemed to be deposits, as defined under the Companies (Acceptance of Deposits) Rules, 2014 from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 are not applicable. According to the



information and explanations given to us and on the basis of the audit procedures performed by us, we report that no order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal on the Company.

- vi. In respect of the Company, maintenance of Cost Records has been specified by the Central Government under sub-section (1) of Section 148 of the Act. We have broadly reviewed the books of account maintained by the company pursuant to the Rules made by the Central Government for the maintenance of cost records under section 148 of the Act and we are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.
- vii. (a) According to information and explanations given to us and on the basis of our audit procedures performed, we report that the Company is regular in depositing undisputed statutory dues including goods and services tax, employees' state insurance, income tax, duty of customs, cess and any other statutory dues to the appropriate authorities. No undisputed amount is payable in respect of the above as at 31<sup>st</sup> March, 2025, for a period of more than six months from the date on when they become payable. In case of provident fund, delays were noticed in few cases due to pending generation of Universal Account Number (UAN).

Name of the Statute	Nature of Dues	Amount (Rs. In Lakhs)	Period for which Amount Related	Due Date	Date of Payment
Provident Fund Act	Provident Fund	2.33	April 2022 to March 2025	May 2022 to April 2025	Unpaid as on 31st March 2025

- (b) Details of statutory dues referred to in sub clause (a) above which have not been deposited as on 31<sup>st</sup> March, 2025 on account of disputes, are given below -

Name of the Statute	Nature of Dues	Total Amount (Rs. In Lakhs)	Amount deposited (Rs. In Lakhs)	Period to which the amount relates	Forum where the dispute is pending
GST Act	Cenvat Credit	2.02	0.61	2017-18	GST Appellate Tribunal
Custom Tax Act	Custom drawback recovery	24.31	Nil	01.04.2014 to 31.03.2018	Assistant Commissioner of Customs
Income Tax Act 1961	Income Tax	10.58	3.00	2014-15	Commissioner of Income Tax (Appeal)
<b>Total</b>		<b>36.91</b>	<b>3.61</b>		

- viii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of accounts, in the tax assessment under the Income Tax Act, 1961 (43 of 1961).





- ix. (a) According to information and explanations given to us and on the basis of our audit procedures performed, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) The Company is not declared as a wilful defaulter by any bank or financial institution or any other lender.
- (c) The Company has not taken any term loan during the year and hence, reporting requirement under para 3(ix)(c) of the Order is not applicable.
- (d) The company has not raised any funds on short term basis during the year and hence, reporting requirement under para 3(ix)(d) is not applicable.
- (e) The Company does not have any Subsidiary, Joint Venture or Associate companies and accordingly reporting requirement under para 3(ix)(e) of the Order is not applicable.
- (f) The Company does not have any Subsidiary, Joint Venture or Associate companies and hence, reporting requirement under para 3(ix)(f) of the Order is not applicable.
- x. (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year and hence, reporting requirement under para 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partly or optionally convertible) and hence, reporting requirement under para 3(x)(b) of the Order is not applicable.
- xi. (a) No fraud by the Company or on the Company has been noticed or reported during the year.
- (b) No report under sub-section (12) of Section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.
- (c) The requirements of establishing whistle blower mechanism is not applicable to the Company as per Section 177(9) of the Act, read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014. Hence, reporting requirement under para (xi)(c) of the Order is not applicable.
- xii. The Company is not a Nidhi Company and hence, reporting requirement under para 3(xii) of the Order is not applicable.
- xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.



- xiv. (a) In our opinion, the Company has an adequate internal audit system commensurate with the size and the nature of its business.
- (b) We have considered the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.
- xv. The Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence the provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. (a) In our opinion, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting requirements under para 3(xvi)(a) and (b) and (c) of the Order are not applicable.
- (b) In our opinion, the Company is not a Core Investment Company (CIC) as defined in the regulations made by Reserve Bank of India and hence, reporting requirement under para 3(xvi)(c) of the Order is not applicable.
- (c) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly, reporting requirement under para 3(xvi)(d) of the Order is not applicable.
- xvii. The Company has not incurred any cash losses during the financial year covered by our audit and in the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors of the Company during the year. Accordingly, the requirements of clause 3(xviii) of the Order are not applicable.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.






- xx. (a) There are no unspent amounts towards Corporate Social Responsibility (CSR) on other than ongoing projects requiring a transfer to a Fund specified in Schedule VII to the Companies Act in compliance with second proviso to sub-section (5) of Section 135 of the said Act. Accordingly, reporting requirement under para 3(xx)(a) of the Order is not applicable for the year.
- (b) There are no amount remaining unspent under sub-section (5) of section 135 of the Companies Act, pursuant to ongoing project and accordingly, reporting requirement under para 3(xx)(b) of the Order is not applicable for the year.

For **R.S. SANGHAI & ASSOCIATES**  
**Chartered Accountants**  
Firm's registration number: 109094W



Place: Mumbai  
Date: 23<sup>rd</sup> May, 2025

  
**R.S. SANGHAI**  
Partner  
M. No.: 036931

UDIN No.	2	5	0	3	6	9	3	1	B	M	G	J	D	G	2	0	9	7
----------	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

**Re: CACHET PHARMACEUTICALS PRIVATE LIMITED**

**"Annexure B" to the Independent Auditors' Report for the year ended 31<sup>st</sup> March, 2025**

Report on the Internal Financial Controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act") referred to in paragraph 2(f) under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date:

**Opinion**

We have audited the internal financial controls with reference to financial statements of **CACHET PHARMACEUTICALS PRIVATE LIMITED** ("the Company") as of 31<sup>st</sup> March, 2025, in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at 31<sup>st</sup> March, 2025, based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**Management's Responsibility for Internal Financial Controls**

The Company's management and Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013

**Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.





Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

#### **Meaning of Internal Financial Controls with reference to financial statements**


A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Ind AS financial statements.

#### **Inherent Limitations of Internal Financial Controls with reference to financial statements**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **R.S. SANGHAI & ASSOCIATES**  
**Chartered Accountants**  
 Firm's registration number: 109094W



  
**R.S. SANGHAI**  
 Partner  
 M. No.: 036931

Place: Mumbai  
 Date: 23<sup>rd</sup> May, 2025

UDIN No.	2	5	0	3	6	9	3	1	B	M	G	J	D	G	2	0	9	7
----------	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**BALANCE SHEET AS AT 31ST MARCH, 2025**

Particulars	Note No.	As at 31st March, 2025	As at 31st March, 2024
		Rs. in Lakhs	Rs. in Lakhs
<b>I. ASSETS</b>			
<b>1 Non-Current Assets</b>			
(a) Property, plant and equipment	3.1	2,832.21	2,836.72
(b) Right of use assets	3.1	358.89	188.46
(c) Capital work in progress	3.1	26.03	2.10
(d) Other Intangible assets	3.1	13.96	10.12
(e) Financial assets			
(i) Investments	3.2	945.81	65.90
(ii) Other non-current financial assets	3.3	3,746.08	1,067.47
(f) Deferred tax assets (net)	3.4E	736.33	718.03
(g) Non Current tax assets (Net)	3.4D	3.00	186.21
(h) Other non-current assets	3.5	4.39	1.75
<b>Total Non-Current Assets</b>		<b>8,666.70</b>	<b>5,076.76</b>
<b>2 Current Assets</b>			
(a) Inventories	3.6	2,308.04	2,380.53
(b) Financial assets			
(i) Investments	3.7	307.17	154.30
(ii) Trade receivables	3.8	6,094.38	5,624.08
(iii) Cash and cash equivalents	3.9	1,293.28	440.14
(iv) Bank balances other than (iii) above	3.10	6,449.98	7,898.12
(v) Loans	3.11	145.20	54.22
(vi) Other current financial assets	3.12	90.96	69.40
(c) Other current assets	3.13	732.57	1,024.87
<b>Total Current Assets</b>		<b>17,421.58</b>	<b>17,645.66</b>
<b>TOTAL ASSETS</b>		<b>26,088.28</b>	<b>22,722.42</b>
<b>II. EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
(a) Equity share capital	3.14	17.83	17.83
(b) Other equity	3.15	12,462.69	8,274.42
<b>Total Equity</b>		<b>12,480.52</b>	<b>8,292.25</b>
<b>2 Liabilities</b>			
<b>2a Non-Current Liabilities</b>			
(a) Financial liabilities			
(i) Lease liabilities	3.16	296.13	140.92
(b) Provisions	3.17	1,641.05	1,437.80
<b>Total Non-Current Liabilities</b>		<b>1,937.18</b>	<b>1,578.72</b>
<b>2b Current Liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	3.18	-	134.45
(ii) Lease liabilities	3.19	84.44	62.88
(iii) Trade payables	3.20		
(a) Total Outstanding Dues of micro and small enterprises		311.81	339.58
(b) Total Outstanding Dues of creditors other than micro and small enterprises		6,107.04	5,422.77
(iv) Other current financial liabilities	3.21	3,844.26	4,785.47
(b) Other current liabilities	3.22	769.53	684.90
(c) Provisions	3.23	218.15	250.25
(d) Current Tax Liabilities (Net)	3.4D	335.35	1,171.15
<b>Total Current Liabilities</b>		<b>11,670.58</b>	<b>12,851.45</b>
<b>Total Liabilities</b>		<b>13,607.76</b>	<b>14,430.17</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>26,088.28</b>	<b>22,722.42</b>
Material Accounting Policies	1		
Key accounting estimates and judgements	2		
Notes to the Financial Statements	3		
The accompanying notes are an integral part of financial statements			





**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**BALANCE SHEET AS AT 31ST MARCH, 2025**

As per our Report attached of even date,  
**For R. S. SANGHAI & ASSOCIATES**  
Chartered Accountants  
Firm Reg No: 109094W



**R.S.Sanghai**  
Partner  
Membership No: 036931  
Place: Mumbai  
Date: 23rd May, 2025



For & on behalf of the Board,  
**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
CIN:U24230BR1978PTC001328



**S.K.Singh**  
Managing Director  
DIN : 00245703



**Arunkumar Deshmukh**  
Independent Director  
DIN : 07210367

**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2025**

Particulars	Note No.	For the year ended 31st March 2025	For the year ended 31st March 2024
		Rs. in Lakhs	Rs. in Lakhs
<b>1 Income:</b>			
(a) Revenue from operations	3.24	45,936.04	44,243.63
(b) Other income	3.25	1,865.69	664.06
<b>Total Income</b>		<b>47,801.73</b>	<b>44,907.69</b>
<b>2 Expenses:</b>			
(a) Cost of materials consumed	3.26	4,499.96	4,290.93
(b) Purchases of stock-in-trade		19,341.32	18,988.92
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3.27	21.70	431.73
(d) Employee benefits expense	3.28	9,513.83	9,358.36
(e) Finance costs	3.29	149.21	131.47
(f) Depreciation and amortization expense	3.1	363.92	353.74
(g) Other expenses	3.30	8,016.05	8,321.01
<b>Total Expenses</b>		<b>41,905.99</b>	<b>41,876.16</b>
<b>3 Profit/(loss) before exceptional items and tax (1) - (2)</b>		<b>5,895.74</b>	<b>3,031.53</b>
<b>4 Profit/(loss) before tax</b>		<b>5,895.74</b>	<b>3,031.53</b>
<b>5 Tax expense:</b>	3.4A		
(a) Current tax		1,671.48	1,186.08
(b) Deferred tax (Net)		22.49	(122.15)
<b>Total tax expense</b>		<b>1,693.97</b>	<b>1,063.93</b>
<b>6 Profit for the year (4) - (5)</b> (Before adjustment of tax relating to earlier years)		<b>4,201.77</b>	<b>1,967.60</b>
<b>7 Tax expense of earlier years</b>	3.4F	(107.78)	1141.08
<b>8 Profit for the year (6) - (7)</b>		<b>4309.55</b>	<b>826.52</b>
<b>9 Other Comprehensive Income/(Loss)</b> Items that will not be reclassified subsequently to profit or loss:			
- Remeasurements of defined benefit plans		(162.07)	(54.31)
- Tax on Remeasurements of defined benefit plans		40.79	13.67
<b>Total of Other Comprehensive Income for the period, net of tax</b>		<b>(121.27)</b>	<b>(40.64)</b>
<b>10 Total Comprehensive Income for the period (8) + (9)</b>		<b>4,188.27</b>	<b>785.88</b>
Earnings per equity share (In Rs.)	3.34		
Basic and diluted earning per share		24,164.78	4,634.51
Face Value of Equity Share (In Rs.)		100.00	100.00
Material accounting policies	1		
Key accounting estimates and judgements	2		
Notes to the Financial Statements	3		
The accompanying notes are an integral part of financial statements			





CACHET PHARMACEUTICALS PRIVATE LIMITED  
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2025

As per our Report attached of even date,  
For **R. S. SANGHAI & ASSOCIATES**  
Chartered Accountants  
Firm Reg No: 109094W



**R.S.Sanghai**  
Partner  
Membership No: 036931  
Place: Mumbai  
Date: 23rd May, 2025



For & on behalf of the Board,  
**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
CIN:U24230BR1978PTC001328



**S.K.Singh**  
Managing Director  
DIN : 00245703



**Arunkumar Deshmukh**  
Independent Director  
DIN : 07210367

**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST MARCH 2025**

**A. Equity Share Capital**

**(1) Current reporting Period**

(Rs. in Lakhs)

Balance as at 31 March 2024	Changes in equity share capital during the current year	Balance as at 31 March 2025
17.83	-	17.83

**(2) Previous reporting Period**

(Rs. in Lakhs)

Balance as at 31 March 2023	Changes in equity share capital during the current year	Balance as at 31 March 2024
17.83	-	17.83

**B. Other equity**

**(1) Current Reporting period**

(Rs. in Lakhs)

Particulars	Reserves & surplus				Items of OCI	Total other equity
	Capital Reserve	Securities Premium	General reserve	Retained Earnings	Remeasurements of defined benefit plans	
Balance as at the 31 March 2024	31.00	2,496.70	2,500.00	3,446.66	(199.94)	8,274.42
Total comprehensive income for the year ended 31 March, 2025	-	-	-	4,309.55	(121.27)	4,188.27
Balance as at 31 March 2025	31.00	2,496.70	2,500.00	7,756.21	(321.21)	12,462.70

**(2) Previous Reporting period**

(Rs. in Lakhs)

Particulars	Reserves & surplus				Items of OCI	Total other equity
	Capital Reserve	Securities Premium	General reserve	Retained Earnings	Remeasurements of defined benefit plans	
Balance as at the 31 March 2023	31.00	2,496.70	2,500.00	2,620.14	(159.30)	7,488.54
Total comprehensive income for the year ended 31 March, 2024	-	-	-	826.52	(40.64)	785.88
Balance as at 31 March 2024	31.00	2,496.70	2,500.00	3,446.66	(199.94)	8,274.42

**Notes :**

The Description of the nature and purpose of each reserve within equity:

**(a) Capital reserve**

Capital reserve represents investment subsidies from state government.

**(b) Securities premium account**

Securities premium represents premium on shares issued.

**(c) General reserve**

The Company has transferred a portion of the net profit of the Company before declaring dividend to general reserve upto 31st March, 2015 pursuant to the earlier provisions of Companies Act, 1956. Mandatory transfer to general reserve is not required under the Companies Act, 2013.

**(d) Retained earning**

Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve.

**(e) Remeasurement of defined benefit plans**

Remeasurement of defined benefit plans represents actuarial gains and losses relating to gratuity

As per our Report attached of even date,

**For R. S. SANGHAI & ASSOCIATES**

Chartered Accountants

Firm Reg No: 109094W

For & on behalf of the Board,

**CACHET PHARMACEUTICALS PRIVATE LIMITED**

CIN:U24230BR1978PTC001328

R. S. Sanghai  
Partner

Membership No: 036931

Place: Mumbai

Date: 23rd May, 2025



S. K. Singh  
Managing Director  
DIN : 00245703

Arunkumar Qeshmukh  
Independent Director  
DIN No.07210367



**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2025**

Particulars	For the year ended 31st March, 2025	For the year ended 31st March 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>A Cash flow from Operating Activities:</b>		
Profit before tax	5,895.73	3,031.51
<u>Adjustments for:</u>		
Depreciation and amortisation	363.91	353.74
Provision for gratuity and compensated absences	9.08	40.15
Allowances for doubtful debts	154.73	60.30
Provision for anticipated sales returns (net of right on refund of returned assets)	(132.75)	99.33
(Gain)/ Loss on sale of property, plant and equipment	(0.66)	1.26
(Gain)/ Loss on Termination of Lease	(1.28)	(0.38)
Dividend income	(0.22)	(0.22)
Interest income	(804.21)	(565.82)
Provisions written back	(927.71)	-
Interest expenses	136.51	120.56
Realised (gain)/loss on mutual fund revaluation (net)	-	(0.89)
Unrealised foreign currency (gain)/loss on revaluation (net)	(25.71)	(20.08)
Unrealised (gain)/loss on mutual fund revaluation (net)	(12.99)	(9.22)
<b>Subtotal of adjustments</b>	<b>(1,241.30)</b>	<b>78.73</b>
<b>Operating profit before working capital changes</b>	<b>4,654.43</b>	<b>3,110.24</b>
<u>Changes in working capital:</u>		
(Increase)/ Decrease in trade receivables	(599.35)	(256.63)
(Increase)/ Decrease in loans, other financial assets and other assets	(164.22)	(36.11)
(Increase)/ Decrease in inventories	72.50	508.49
Increase/ (Decrease) in trade payables and other liabilities	1,194.67	(194.37)
<b>Subtotal of adjustments</b>	<b>503.60</b>	<b>21.37</b>
<b>Cash generated from operations</b>	<b>5,158.03</b>	<b>3,131.61</b>
Less: Income taxes paid (Net of refund)	(2,216.28)	(1,175.91)
<b>Net cash (used in)/ generated from operating activities</b>	<b>2,941.75</b>	<b>1,955.70</b>
<b>B Cash Flow from Investing Activities:</b>		
Purchases of property, plant and equipments	(355.00)	(512.67)
Sale of property, plant and equipments	52.78	53.70
(Investments) made/ Redemption of bank deposits having maturity of more than 3 months	(1,223.40)	(2,219.50)
(Investments) made/ Redemption of mutual funds - debt	(100.00)	(24.12)
(Investments) made/ Redemption of Bonds	(919.79)	(74.79)
Dividend received	0.22	0.22
Interest received	804.21	565.82
<b>Net cash (used in)/ generated from investing activities</b>	<b>(1,740.98)</b>	<b>(2,211.34)</b>
<b>C Cash Flow from Financing Activities:</b>		
(Repayment) of/ Proceeds from current borrowings (net)	(134.45)	131.70
Repayment of lease liabilities	(99.10)	(107.22)
Interest paid	(114.08)	(101.09)
<b>Net cash (used in)/ generated from financing activities</b>	<b>(347.63)</b>	<b>(76.61)</b>
<b>D Net increase/ (decrease) in cash and cash equivalents (A+B+C)</b>	<b>853.14</b>	<b>(332.25)</b>
<b>E Cash and cash equivalents as at the beginning of the year (Refer note 3.9)</b>	<b>440.14</b>	<b>772.41</b>
<b>F Cash and cash equivalents as at the end of the year (D+E) (Refer note 3.9)</b>	<b>1,293.28</b>	<b>440.14</b>



**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2025**

**Notes:**

1. Cash & Cash Equivalents include cash and Bank Balances in Current Accounts and in Deposit Accounts (Refer Note 3.9 of the notes to financial statements).
2. Additions to Property, plant and equipments (Including Capital Work In Progress) are considered as a part of investing activities.
3. Interest Income on Bank Deposits is classified as cash flow from Investing Activities.
4. Above Cash Flow Statements is prepared under the "Indirect Method" as set out in Indian Accounting Standard 7 (IND AS-7) "Statement of Cash Flow".
5. Previous year's figures have been regrouped or rearranged wherever necessary.

Material accounting policy information	1
Key accounting judgements and estimates	2
Notes to the Financial Statements	3

**The accompanying notes are an integral part of financial statements**

As per our Report attached of even date,  
**For R. S. SANGHAI & ASSOCIATES**  
Chartered Accountants  
Firm Reg No: 109094W



For & on behalf of the Board,  
**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
CIN:U24230BR1978PTC001328

**S. K. Singh**  
Managing Director  
DIN : 00245703

**Arunkumar Deshmukh**  
Independent Director  
DIN : 07210367

**R. S. Sanghai**  
Partner  
Membership No: 036931  
Place: Mumbai  
Date: 23rd May, 2025



**NOTE 1: MATERIAL ACCOUNTING POLICIES:**

**1 Company Overview and Material Accounting Policies**

**1A Company overview**

M/s. Cachet Pharmaceuticals Private Limited ('the Company') was incorporated in 1978 under the provisions of Companies Act, 1956 of India, as a Company with limited liability. The Company is domiciled in India with its registered office address being Exhibition Road, P.S. Gandhi Maidan, Patna - 800001, India. The Company is engaged in manufacture and sale of pharmaceutical products.

**1B Material accounting policies**

**1.1 Basis of preparation of financial statements:**

**a) Statement of compliance**

The financial statements of the Company as at and for the year ended March 31, 2025 have been prepared in accordance with Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs in consultation with the National Advisory Committee on Accounting Standards, under section 133 of the Companies Act, 2013 ('Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the relevant provisions of the Act.

The financial statements are prepared in Indian rupees, rounded off to the nearest lakhs except for EPS (Earnings per share), unless otherwise stated.

The financial statements are authorised for issue by the Board of Directors of the Company at its meeting held on May 23, 2025.

**b) Basis of preparation and presentation**

The preparation of financial statements in accordance with Ind AS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in **Note 2**. Actual results could differ from those estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

The Company presents assets and liabilities in Balance Sheet based on current/non-current classification.

An asset is classified as current when it is:

- i) Expected to be realised or intended to be sold or consumed in normal operating cycle\*,
- ii) Held primarily for the purpose of trading,
- iii) Expected to be realised within twelve months after the reporting period, or
- iv) Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

\*The operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months

All other assets are classified as non-current.

A liability is classified as current when:

- i) It is expected to be settled in normal operating cycle,
- ii) It is held primarily for the purpose of trading,
- iii) It is due to be settled within twelve months after the reporting period,
- iv) There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.



**c) Operating Cycle**

Based on the nature of products/activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current as set out in Schedule III of the act.

**d) Basis of measurement**

These financial statements have been prepared on a historical cost basis and on accrual basis, except for the following:

- Financial assets and liabilities are measured at fair value or at amortised cost depending on classification;
- Defined benefit plans are measured at fair value of plan assets; and
- Lease liability and Right-of-use assets are measured at amortised cost.

**e) Functional and presentation currency**

These financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates.

**1.2 Property, plant and equipment ("PPE"):**

**a) Recognition and Measurement**

- All items of Property, plant and equipment, including freehold land, are initially recorded at cost. The cost of an item of Property, plant and equipment comprises its purchase price, including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the assets to its working condition for its intended use and any trade discount and rebates are deducted in arriving at purchase price. Cost of the assets also includes interest on borrowings attributable to acquisition of qualifying assets up to the date the asset is ready for its intended use incurred up to that date.
- Subsequent to initial recognition, items of Property, plant and equipment other than freehold land are carried at cost less accumulated depreciation and impairment losses, if any. Freehold land has an unlimited useful life and therefore is not depreciated.
- If significant parts of an item of PPE have different useful lives, then they are accounted for as separate items (major components) of PPE.
- Any gain or loss on disposal of an item of property, plant and equipment is recognised in the statement of profit and loss.
- Cost of items of Property, plant and equipment not ready for intended use as on the balance sheet date, is disclosed as capital work in progress. Advances given towards acquisition of Property, plant and equipment outstanding at each balance sheet date are disclosed as Capital Advance under "Other non-current assets".
- The cost of an item of PPE is recognised as an asset if, and only if, it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.
- The cost of property, plant and equipment at 1 April 2016, the Company's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

**b) Subsequent expenditure**

Subsequent expenditure relating to PPE is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance and the cost of the asset can be measured reliably.

**c) Depreciation**

Depreciation is the systematic allocation of the depreciable amount of PPE over its useful life and is provided on a straight-line basis over the useful lives as prescribed under Schedule II to the Act or as per technical assessment. The residual values, useful lives and method of depreciation of PPE is reviewed at each financial year end and adjusted prospectively, if appropriate.





Depreciation on additions/disposals is provided on a pro-rata basis i.e. from/up to the date on which an asset is ready to use/dispose of. Freehold land is not depreciated.

The estimated useful lives of Tangible assets are as follows:

PPE	Useful life
Factory Buildings	30 years
Office Buildings	60 years
Plant and machinery	15 years
Furniture and fixtures	10 years
Computers	3 years
Servers & Networks	6 years
Vehicles	8 years
Other office equipment's	5 years

### **1.3 Intangible assets:**

#### **a) Recognition and measurement**

Intangible assets such as computer software that are acquired by the Company and have finite useful life are measured at cost less accumulated amortisation and any accumulated impairment losses.

The cost of Intangible assets as at 1 April 2016, the Company's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

#### **b) Subsequent expenditure**

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific assets to which it relates and the cost of the asset can be measured reliably. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in the Statement of profit and loss as incurred.

#### **c) Amortisation**

Amortisation is calculated to write off the cost of intangible assets less their estimated residual values using the straight-line method over their estimated useful lives, and is generally recognised in the Statement of profit and loss. The amortisation period and the amortisation method for finite-life intangible assets is reviewed at each financial year end & adjusted prospectively, if appropriate.

The estimated useful lives of intangible assets are as follows:

Intangible assets	Useful life
Computer software	3 to 6 Years

### **1.4 Impairment of non-financial assets:**

At each reporting date, the Company reviews the carrying amounts of its non-financial assets (other than inventories and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or Cash generating units ("CGU").

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its recoverable amount. Impairment losses are recognised in profit or loss. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.



**1.5 Leases and Right of use (ROU):**

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether:

- (i) the contract involves the use of an identified asset;
- (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease; and
- (iii) the Company has the right to direct the use of the asset.

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

Certain lease arrangements include the options to extend the lease before the end of the lease term, but the renewal aspect has not been added to the lease term since the option to renew the lease lies with both the lessor and the lessee.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. Right of use assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using discount rates generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristics. Lease liabilities are remeasured with a corresponding adjustment to the related right of use asset if the Company changes its assessment of whether it will exercise an extension or a termination option. Lease liability and ROU asset have been separately presented in the Balance Sheet.

**1.6 Financial instruments:**

**Recognition and initial measurement**

Trade receivables and debt securities issued are initially recognised when they are originate. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. However, trade receivables that do not contain a significant financing component are measured at transaction price.

**Classification and subsequent measurement**

**Financial Assets**

On initial recognition, a financial asset is classified as measured at

- Amortised cost;
- Fair value through Other Comprehensive Income (FVOCI) - Debt investment;
- Fair value through Other Comprehensive Income (FVOCI) - Equity investment; or
- Fair value through Profit and Loss (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and





- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

#### **Financial assets: Business model assessment**

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- The stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- How the performance of the portfolio is evaluated and reported to the Company's management;
- The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- How managers of the business are compensated –e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- The frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for de-recognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

#### **Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest**

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows that it would not meet this condition. In making this assessment, the Company considers:

- Contingent events that would change the amount or timing of cash flows;
- Terms that may adjust the contractual coupon rate, including variable interest rate features;
- Prepayment and extension features; and
- Terms that limit the Company's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.





**Financial assets: subsequent measurement and gains and losses**

**i) Financial assets at FVTPL**

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

**ii) Financial assets at amortised cost**

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on de-recognition is recognised in profit or loss.

**iii) Debt investments at FVOCI**

These assets are subsequently measured at fair value. Interest income under the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On de-recognition, gains and losses accumulated in OCI are reclassified to profit or loss.

**iv) Equity investments at FVOCI**

These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to profit or loss.

**Financial Liabilities**

**Classification, subsequent measurement and gains and losses**

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gains or loss on de-recognition is also recognized in profit or loss.

**De-recognition**

**Financial assets**

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership but does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognized on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognized.

**Financial liabilities**

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expired. The Company also derecognises a financial liability when its terms are modified and the cash flow under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit or loss.

**Offsetting**

Financial assets and liabilities are offset and the net amount presented in the Balance Sheet when, and only when, the Company currently has a legally enforceable right to offset the amounts and it intends either to settle them on a net basis or to realise the asset and liability simultaneously.

**1.7 Equity instruments:**

Equity instruments issued by the Company are classified according to the substance of the contractual arrangements entered into and the definitions of an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities and includes no obligation to deliver cash or other financial assets.





**1.8 Inventories:**

- a) Raw Materials and Packing Materials are valued at lower of cost or net realizable value. However, if the finished goods in which they will be incorporated are expected to be sold at or above cost they are valued at cost. If the decline in price of materials indicate that the cost of finished goods exceeds net realisable value, the materials are written down to net realisable value; cost is calculated on moving weighted average basis.
- b) Finished Goods and Work-in-Progress are valued at lower of cost (on moving weighted average basis) and net realisable value. In respect of finished goods, cost includes materials, appropriate share of utilities and other overheads. Trading Goods are valued at lower of cost (on moving weighted average basis) and net realisable value. Cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.
- c) Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale on item-by-item basis.

**1.9 Revenue recognition and measurement:**

**a) Sale of Products & services**

Revenue from sale of goods is recognized when control of the goods are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company assesses promises in the contract that are separate performance obligations to which a portion of transaction price is allocated.

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold and services rendered is net of variable consideration on account of various discounts and schemes offered by the Company as part of the contract. Accumulated experience is used to estimate the provision for discounts, probable saleable and non-saleable return of goods from the customers. Revenue is only recognised to the extent that it is highly probable a significant reversal will not occur.

**b) Other Operating revenue**

Income from services rendered is recognised based on agreements/arrangements with the customers as the service is performed and there are no unfulfilled obligations.

Export benefits available under prevalent schemes are accrued in the year in which the goods are exported and no significant uncertainty exist regarding its ultimate collection.

Royalty income in relation to sales based or usage-based royalties in exchange for a licence of intellectual properties is recognised only when the later of the following event occurs:

- i) The subsequent sale or usage occurs; and
- ii) The performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied).

**c) Other Income**

Revenue (including in respect of insurance or other claims, etc.) is recognised when it is reasonable to expect that the ultimate collection will be made.

Interest income is recognized using the effective interest rate (EIR) method.

Dividend from investment is recognised as revenue when right to receive the payments is established.

**d) Contract Balances**

**Assets and liabilities arising from right to return:**

The Company has contracts with customers which entitles them the unconditional right to return.

**Right to return assets:**

A right of return gives an entity a contractual right to recover the goods from a customer (return asset), if the customer exercises its option to return the goods and obtain a refund. The asset is measured at the carrying amount of the inventory, less any expected costs to recover the goods, including any potential decreases in the value of the returned goods.





**Refund liabilities:**

A refund liability is the obligation to refund part or all of the consideration received (or receivable) from the customer. The Company has therefore recognised refund liabilities in respect of customer's right to return. The liability is measured at the amount the Company ultimately expects it will have to return to the customer. The Company updates its estimate of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.

The Company has presented its right to return assets and refund liabilities as required under Ind AS 115 in the financial statements.

**1.10 Foreign currency transactions and translations:**

Transactions in foreign currencies are translated into the functional currency of the Company by applying the appropriate fortnightly rate which best approximates the actual rate of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Foreign currency differences are generally recognised in the Statement of profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not translated.

**1.11 Employee Benefits:**

**a) Post-employment Benefits and Other Long-Term Benefits:**

**i) Defined Contribution Plan:**

Company's contribution for the year paid/ payable to defined contribution retirement benefit schemes are charged to Statement of profit and loss in period in which the related service is provided by the employee. The Company's legal or constructive obligation is limited to the contribution it makes.

The Company's contributions towards provident fund for eligible employees are considered to be defined contribution plan for which the Company makes contribution on monthly basis. Certain employees of the Company are participants of a Superannuation Plan. The Company has no further obligations to the Plan beyond its monthly contributions which are periodically contributed to a trust fund, the corpus of which is invested as recommended by the Trustees.

**ii) Defined Benefit and Other Long Term Benefit Plans:**

The Company's net obligation in respect of gratuity plan, which is a defined benefit plan, is calculated using the Projected Unit Credit Method and the same is carried out annually by a qualified actuary. The current service cost and interest on the net defined benefit liability / (asset) is recognised in the statement of profit and loss. Past service cost are immediately recognised in the statement of profit and loss. Actuarial gains and losses net of deferred taxes arising from experience adjustment and changes in actuarial assumptions are recognised in other comprehensive income in the period in which they arise. The Gratuity Plan provides a lump-sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment with the Company. The Company contributes Gratuity liabilities to the Cachet Pharmaceuticals Private Limited Employees' Gratuity Trust (the Trust). Trustees administer contributions made to the Trusts and contributions are invested in a scheme with the Future Generali India Life Insurance as permitted by Indian law.

The Company's current policy permits eligible employees to accumulate compensated absences up to a prescribed limit and receive cash in lieu thereof in accordance with the terms of the policy. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company expects to pay as a result of unused entitlement that has accumulated as at the reporting date. The expected cost of these benefits is calculated using Projected Unit Credit Method by a qualified actuary every year. Actuarial gains and losses arising from experience adjustment and changes in actuarial assumptions are recognised in the statement of profit and loss in the period in which they arise. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

**b) Short term employee benefits:**

Short term employee benefits are benefits payable and recognised in 12 months. Short-term employee benefits expected to be paid in exchange for the services rendered by employees are recognised undiscounted during the year as the related service are rendered by the employee. These benefits includes performance incentives. These are expensed as employee benefit expense in the statement of profit and loss in the period in which the related service is provided by the employees.





**1.12 Taxes on Income:**

Income tax expense represents the sum of the current tax and deferred tax.

**a) Current tax**

Current tax comprises the expected payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to the income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

**b) Deferred tax**

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred tax is also recognised in respect of carried forward tax losses and tax credits. However, deferred tax is not recognised:

- in case of temporary differences that arise from initial recognition of assets or liabilities in a transaction (other than business combination) that affect neither the taxable profit nor the accounting profit
- in case of temporary differences if any that may arise from initial recognition of goodwill, deferred tax liabilities are not recognised
- in case of temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future.

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

**1.13 Borrowing Costs:**

Borrowing costs are interest and other costs incurred by the Company in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of those tangible fixed assets which necessarily take a substantial period of time to get ready for their intended use are capitalised. Other borrowing costs are recognised as an expense in the Statement of Profit and Loss of the period in which they are incurred.

**1.14 Provision, Contingent Liabilities and Contingent Assets:**

A provision is recognised if, as a result of a past event, the Company has a present obligation (legal or constructive) that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. If the effect of time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability.

A contingent liability exists when there is a possible but not probable obligation or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognised nor disclosed in the financial statements. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and its recognition is appropriate.

Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.



**1.15 Earnings per share ('EPS'):**

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

**1.16 Government Grants:**

Government grants and subsidies are recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants / subsidy will be received. Grants related to depreciable assets are treated as deferred income which is recognised in the Statement of profit and loss on a systematic and rational basis over the useful life of the asset. Such allocation to income is usually made over the periods and in the proportions in which depreciation on related assets is charged. Government Grants of revenue nature is reduced from related expenses in the statement of Profit and Loss in the year of its receipt or when there is a reasonable assurance of its being received.

**1.17 Non-current assets held for sale:**

Non-current assets are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use. Such assets are generally measured at the lower of their carrying amount and fair value less cost to sale. Losses on initial classification as held for sale and subsequent gains and losses on re-measurement are recognised in the statement of profit & loss.

Once classified as held for sale, property, plant and equipment are no longer depreciated.

**1.18 Cash and cash equivalents:**

Cash and cash equivalents for the purpose of cash flow statement comprise cash at bank including fixed deposits (having original maturity of less than 3 months), cheques in hand and cash in hand.





**Note 2: Key accounting estimates and judgements**

The preparation of financial statements in conformity with the Ind AS requires judgements, estimates and assumptions to be made that affect the reported amounts of assets and liabilities on the date of the financial statements, the reported amounts of revenues and expenses during the reporting period and the disclosures relating to contingent liabilities as of the date of the financial statements. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in outcomes different from the estimates. Difference between actual results and estimates are recognised in the period in which the results are known or materialise. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognised prospectively in the current and future periods.

Management considers the accounting estimates and assumptions discussed below to be its critical accounting estimates and, accordingly, provide an explanation of each below. The discussion below should also be read in conjunction with the Company's disclosure of material accounting policy information which are provided in **Note 1B** to the financial statements, 'Material accounting policies'.

**I. Estimates**

**a) Estimate of current and deferred tax (Refer Note 1.12)**

The Company's tax charge on ordinary activities is the sum of the total current and deferred tax charges. The calculation of the Company's total tax charge necessarily involves a degree of estimation and judgement in respect of certain items whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. The final resolution of some of these items may give rise to material profits/losses and/or cash flows.

The complexity of the Company's structure makes the degree of estimation and judgement more challenging. The resolution of issues is not always within the control of the Company and it is often dependent on the efficiency of the legal processes in the relevant taxing jurisdictions in which the Company operates. Issues can, and often do, take many years to resolve. Payments in respect of tax liabilities for an accounting period result from payments on account and on the final resolution of open items. As a result, there can be substantial differences between tax charge in the Statement of Profit and Loss and tax payments.

**b) Recognition of deferred tax assets (Refer Note 1.12)**

The recognition of deferred tax assets is based upon whether it is more likely than not that sufficient and suitable taxable profits will be available in the future against which the reversal of temporary differences can be deducted. To determine the future taxable profits, reference is made to the latest available profit forecasts. Where the temporary differences are related to losses, relevant tax law is considered to determine the availability of the losses to offset against the future taxable profits.

**c) Estimation of useful life (Refer Note 1.3)**

The useful life used to amortise or depreciate intangible assets or property, plant and equipment respectively relates to the expected future performance of the assets acquired and management's judgement of the period over which economic benefit will be derived from the asset. The charge in respect of periodic depreciation is derived after determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. Increasing an asset's expected life or its residual value would result in a reduced depreciation charge in the Statement of Profit and Loss.

The useful lives and residual values of Company's assets are determined by management at the time the asset is acquired and reviewed annually for appropriateness. The lives are based on historical experience with similar assets as well as anticipation of future events which may impact their life such as changes in technology.

**d) Defined Benefit Plans (Refer Note 1.11)**

The cost of the defined benefit gratuity plan and other post-employment benefits and present value of the gratuity obligation are determined using actuarial valuation. An actuarial valuation involves making various assumptions that may differ from actual development in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

**e) Liabilities towards anticipated sales return (Refer Note 1.9)**

In determining the provision for anticipated sales returns, estimates for probable saleable and non-saleable returns of goods from the customers are made on scientific basis after factoring in the historical data of such returns and its trend.



II. Judgements

a) **Provisions and contingent liabilities (Refer Note 1.14)**

The Company exercises judgement in measuring and recognising provisions and the exposures to contingent liabilities related to pending litigation or other outstanding claims subject to negotiated settlement, mediation, arbitration or government regulation, as well as other contingent liabilities. Judgement is necessary in assessing the likelihood that a pending claim will succeed, or a liability will arise, and to quantify the possible range of the financial settlement. Because of the inherent uncertainty in this evaluation process, actual losses may be different from the originally estimated provision.

b) The Company uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Company determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Company revises the lease term if there is a change in the non-cancellable period of a lease





**CACHET PHARMACEUTICALS PRIVATE LIMITED**

**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**

**3.1 Property, Plant and Equipment, Right of use Asset, Intangible Assets and Capital Work in Progress**

Particulars	Property, plant and equipment							Intangible assets	Right of use assets	Capital work in progress
	Freehold Land	Buildings	Plant and Machinery	Furniture and Fixtures	Vehicles	Office Equipments	Total	Computer Software		
<b>Gross Block</b>										
As at 1st April 2023	154.26	1,340.82	1,849.63	112.15	332.90	116.14	3,905.90	159.63	384.50	149.53
Additions	-	-	470.54	6.52	155.32	19.72	652.10	8.00	82.02	183.02
Adjustments	-	-	-	-	-	-	-	-	-	-
Deletions	-	-	(99.34)	(0.86)	(89.13)	(1.05)	(190.38)	-	(25.71)	(330.45)
<b>As at 31st March 2024</b>	<b>154.26</b>	<b>1,340.82</b>	<b>2,220.83</b>	<b>117.81</b>	<b>399.09</b>	<b>134.81</b>	<b>4,367.62</b>	<b>167.63</b>	<b>440.81</b>	<b>2.10</b>
<b>As at 1st April, 2024</b>										
Additions	154.26	1,340.82	2,220.83	117.81	399.09	134.81	4,367.62	167.63	440.81	2.10
Adjustments	-	-	141.35	13.75	148.28	20.72	324.10	6.97	258.59	142.30
Deletions	-	-	(87.24)	-	(130.42)	(0.59)	(218.25)	-	(108.95)	(118.37)
<b>As at 31st March, 2025</b>	<b>154.26</b>	<b>1,340.82</b>	<b>2,274.94</b>	<b>131.56</b>	<b>416.95</b>	<b>154.94</b>	<b>4,473.47</b>	<b>174.60</b>	<b>590.45</b>	<b>26.03</b>
<b>Depreciation and amortisation</b>										
As at 1st April 2023	-	281.69	902.22	82.27	76.33	61.38	1,403.89	156.37	166.44	-
Depreciation/amortisation for the year	-	53.67	119.52	5.65	57.81	25.77	262.42	1.14	90.18	-
Adjustments	-	-	-	-	-	-	-	-	-	-
Deductions	-	-	(86.01)	(0.82)	(47.60)	(0.98)	(135.41)	-	(4.27)	-
<b>As at 31st March 2024</b>	<b>-</b>	<b>335.36</b>	<b>935.73</b>	<b>87.10</b>	<b>86.54</b>	<b>86.17</b>	<b>1,530.90</b>	<b>157.51</b>	<b>252.35</b>	<b>-</b>
<b>As at 1st April, 2024</b>										
Depreciation/amortisation for the year	-	335.36	935.73	87.10	86.54	86.17	1,530.91	157.51	252.35	-
Adjustments	-	53.53	136.64	4.58	61.09	20.65	276.49	3.13	84.30	-
Deductions	-	-	(79.90)	-	(85.67)	(0.56)	(166.13)	-	(105.09)	-
<b>As at 31st March, 2025</b>	<b>-</b>	<b>388.89</b>	<b>992.48</b>	<b>91.68</b>	<b>61.96</b>	<b>106.26</b>	<b>1,641.26</b>	<b>160.64</b>	<b>231.56</b>	<b>-</b>
<b>Net Book Value</b>										
As at 31st March, 2024	154.26	1,005.46	1,285.10	30.71	312.55	48.64	2,836.72	10.12	188.46	2.10
<b>As at 31st March, 2025</b>	<b>154.26</b>	<b>951.93</b>	<b>1,282.47</b>	<b>39.88</b>	<b>354.99</b>	<b>48.68</b>	<b>2,832.21</b>	<b>13.96</b>	<b>358.89</b>	<b>26.03</b>

Note: Title deeds of all the immovable properties are in the name of the company.



CACHET PHARMACEUTICALS PRIVATE LIMITED  
NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025

3.1 Property, Plant and Equipment, Right of use Asset, Intangible Assets and Capital Work in Progress

Capital Work in Progress Schedule:

Ageing schedule as at 31st March, 2025

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
Projects in Progress	26.03	-	-	-	26.03
Projects temporarily suspended	-	-	-	-	-
Total	26.03	-	-	-	26.03

Completion schedule as at 31st March, 2025

CWIP	To be completed in				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
Plant & machinery under installation in Factory	26.03	-	-	-	26.03
Furniture under construction at Depot	-	-	-	-	-
Total	26.03	-	-	-	26.03

Ageing schedule as at 31st March, 2024

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
Projects in Progress	2.10	-	-	-	2.10
Projects temporarily suspended	-	-	-	-	-
Total	2.10	-	-	-	2.10

Completion schedule as at 31st March, 2024

CWIP	To be completed in				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
Plant & machinery under installation in Factory	2.10	-	-	-	2.10
Furniture under construction at Depot	-	-	-	-	-
Total	2.10	-	-	-	2.10





**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**

PARTICULARS	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.2 : NON CURRENT INVESTMENTS:</b>		
In Equity shares of Other Companies: Unquoted (at fair value through profit & loss)	1.15	1.15
In Secured Redeemable Non-Convertible Taxable Bonds (at Amortized Cost) : Quoted	340.70	15.01
In Unsecured Non-Redeemable Non-Convertible Taxable Bonds (at Amortized Cost): Quoted	302.46	49.74
In Unsecured Redeemable Non-Convertible Taxable Bonds (at Amortized Cost) : Quoted	301.50	-
<b>TOTAL</b>	<b>945.81</b>	<b>65.90</b>
1) Aggregate value of Quoted Investments	944.66	64.75
2) Aggregate market value of Quoted Investments	NA	NA
3) Aggregate value of unquoted investments	1.15	1.15
<b>3.3 : OTHER NON CURRENT FINANCIAL ASSETS :</b>		
(Unsecured, considered good unless otherwise stated)		
(a) Security deposits	64.13	57.07
(b) Bank Deposits with remaining maturity more than 12 months	3,681.95	1,010.40
<b>TOTAL</b>	<b>3,746.08</b>	<b>1,067.47</b>



CACHET PHARMACEUTICALS PRIVATE LIMITED  
NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025  
3.4 Income Tax

Components of Income Tax Expense

(A) Tax Expense recognised in profit and loss

Particulars	For the year ended 31st March, 2025	(Rs. in Lakhs) For the year ended 31st March, 2024
Current income tax	1,671.48	1,186.08
Deferred income tax liability / (asset), net Origination and reversal of temporary differences	22.49	(122.15)
<b>Tax expense for the year</b>	<b>1,693.97</b>	<b>1,063.93</b>

(B) Tax Expense recognised in other comprehensive income

Particulars	For the year ended 31st March, 2025			For the year ended 31st March, 2024		
	Before tax	Tax (expense) benefit	Net of tax	Before tax	Tax (expense) benefit	Net of tax
Items that will not be reclassified to profit or loss						
Remeasurements of the defined benefit plans	(162.07)	40.79	(121.27)	(54.31)	13.67	(40.64)
	(162.07)	40.79	(121.27)	(54.31)	13.67	(40.64)

(C) Reconciliation of effective tax rate

Particulars	Rate	For the year ended 31st March, 2025	Rate	For the year ended 31st March, 2024
<b>Profit before tax</b>		<b>5,895.73</b>		<b>3,031.51</b>
Tax using the Company's domestic tax rate (Current year: 25.17% and Previous year: 25.17%)	25.17%	1,483.84	25.17%	762.97
Impact of increase/ decrease in tax rate on opening balance of deferred tax assets/ liabilities	0.00%	-	0.00%	-
<b>Tax effect of:</b>				
Prior period tax adjustment	0.00%	-	0.00%	-
Expense/income not deductible/included for tax purposes	0.00%	-	0.00%	-
Permanent Disallowance	3.56%	210.13	9.93%	300.96
Others	0.00%	-	0.00%	-
	28.73%	1,693.97	35.10%	1,063.93

(D) Tax assets/ (liabilities)

Particulars	As at 31st March, 2025	(Rs. in Lakhs) As at 31st March, 2024
<b>Non-current tax assets/ (Current tax liabilities)</b>		
Non-Current Tax Assets	3.00	186.21
Current Tax Liabilities-Net of Income Tax Assets	(335.35)	(1,171.15)
	(332.35)	(984.94)





**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**  
**3.4 Tax expense**

**(E) Movement in deferred tax assets & liabilities**

(Rs. in Lakhs)  
**31st March 2025**

Particulars	Net balance April 1, 2024	Recognised in profit or loss	Recognised in OCI	Adjustment/ Utilisation	Net	Deferred tax asset	Deferred tax liability
<b>Deferred tax liabilities</b>							
Property, plant and equipment	(269.75)	1.58	-	-	(268.17)	-	(268.17)
<b>Deferred tax assets</b>							
Trade Receivable (Provision for doubtful debts)	116.77	38.95	-	-	155.71	155.71	-
Lease Liability-Lease Property	51.29	44.49	-	-	95.78	95.78	-
Right To Use-Lease Property	(47.43)	(42.89)	-	-	(90.33)	-	(90.33)
Employee benefits	499.26	(26.12)	40.79	-	513.94	513.94	-
Provision on anticipated sales return	472.32	(117.54)	-	-	354.78	354.78	-
Right on refund of returned assets	(132.23)	84.13	-	-	(48.09)	-	(48.09)
Provisions disallowed u/s 40a(ia)	12.17	(1.80)	-	-	10.37	10.37	-
Overdue payments to MSME	0.02	(0.02)	-	-	-	-	-
Other Provisions	15.61	-	-	-	15.61	15.61	-
Fair Value of Shares & Mutual Funds	-	(3.27)	-	-	(3.27)	-	(3.27)
<b>Deferred tax assets/ (liabilities)</b>	<b>718.03</b>	<b>(22.49)</b>	<b>40.79</b>	<b>-</b>	<b>736.33</b>	<b>1,146.19</b>	<b>(409.86)</b>
Offsetting of deferred tax assets & deferred tax liabilities	-	-	-	-	-	(409.86)	409.86
<b>Net deferred tax assets / (liabilities)</b>	<b>718.03</b>	<b>(22.49)</b>	<b>40.79</b>	<b>-</b>	<b>736.33</b>	<b>736.33</b>	<b>-</b>

**Movement in deferred tax assets & liabilities**

(Rs. in Lakhs)  
**31st March 2024**

Particulars	Net balance 1st April, 2023	Recognised in profit or loss	Recognised in OCI	Adjustment/ Utilisation	Net	Deferred tax asset	Deferred tax liability
<b>Deferred tax liabilities</b>							
Property, plant and equipment	(275.43)	5.68	-	-	(269.75)	-	(269.75)
<b>Deferred tax assets</b>							
Trade Receivable (Provision for doubtful debts)	101.59	15.18	-	-	116.77	116.77	-
Lease liability - Lease property	58.23	(6.94)	-	-	51.29	51.29	-
Right of use assets - Lease property	(54.88)	7.45	-	-	(47.43)	-	(47.43)
Employee benefits	426.17	59.42	13.67	-	499.26	499.26	-
Provision on anticipated sales return	453.49	18.83	-	-	472.32	472.32	-
Right on refund of returned assets	(138.40)	6.17	-	-	(132.23)	-	(132.23)
Provisions disallowed u/s 40a(ia)	11.43	0.73	-	-	12.17	12.17	-
Overdue payments to MSME	-	0.02	-	-	0.02	0.02	-
Other Provisions	-	15.61	-	-	15.61	15.61	-
<b>Deferred tax assets/ (liabilities)</b>	<b>582.20</b>	<b>122.15</b>	<b>13.67</b>	<b>-</b>	<b>718.03</b>	<b>1,167.44</b>	<b>(449.41)</b>
Offsetting of deferred tax assets & deferred tax liabilities	-	-	-	-	-	(449.41)	449.41
<b>Net deferred tax assets / (liabilities)</b>	<b>582.20</b>	<b>122.15</b>	<b>13.67</b>	<b>-</b>	<b>718.03</b>	<b>718.03</b>	<b>-</b>

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recoverability of deferred income tax assets. The recoverability of deferred income tax assets is based on estimates of taxable income by each jurisdiction in which the relevant entity operates and the period over which deferred income tax assets will be recovered.

**(F) Tax expense for earlier years: Rs. (107.78) Lakhs (P.Y. Rs. 1141.08 Lakhs)**

During the previous year, the Income Tax department had conducted a survey on the company in the month of September, 2023. Based on the findings in survey, the assessments have been reopened for earlier five years (from F.Y. 2016-17 to 2020-21) for disallowing expense on sales promotion relying on the judgment of the Hon'ble Supreme Court in the case of Apex Laboratories Pvt. Ltd. v/s DCIT (2022) 442 ITR 001 dt. 22nd February, 2022. The company had made a provision for income tax with interest for those years based on the notice for reopening issued u/s 148 read with order u/s 148A(d) dt. 17th April, 2024 for Rs.1,099.94 Lakhs. Further a sum of Rs.41.14 Lakhs is provided for short provisioning in earlier year. All the reassessments were closed during the FY 2024-25 and the difference in the amount provided and actual have been recorded as adjustment to Tax expense for earlier years.



**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**

PARTICULARS	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.5 : OTHER NON-CURRENT ASSETS</b>		
Capital advances		
	4.39	1.75
<b>TOTAL</b>	<b>4.39</b>	<b>1.75</b>
<b>3.6 : INVENTORIES:</b>		
Raw and packing materials	603.49	654.29
Work-in-progress	87.48	48.81
Finished goods	392.18	407.13
Goods in transit (Finished goods)	17.74	20.54
Stock-in-trade	1,077.11	1,218.62
Goods in transit (Stock-in-trade)	130.04	31.14
<b>TOTAL</b>	<b>2,308.04</b>	<b>2,380.53</b>
<b>Note:</b> The Company follows suitable provisioning norms for writing down the value of inventories towards slow moving, non moving, expired and non saleable inventory. Write down of inventory for the year ended 31 March 2025 is <b>Rs. 147.18 Lakhs</b> (Previous year Rs. 188.25 Lakhs)		
<b>3.7 : INVESTMENTS</b>		
In Mutual Funds : Quoted (at fair value through profit & loss)	257.25	144.25
In Unsecured Non-redeemable Non-Convertible Taxable Bonds (at Amortized Cost) : Quoted	49.92	10.05
<b>TOTAL</b>	<b>307.17</b>	<b>154.30</b>
1) Aggregate value of Quoted Investments	307.17	154.30
2) Aggregate market value of Quoted Investments Mutual Fund	257.25	144.25
3) Aggregate market value of Quoted Investments - Bonds	NA	NA
<b>3.8 : TRADE RECEIVABLES:</b>		
<b>Unsecured trade receivables:</b>		
(Unsecured)		
Trade receivables considered good	6,713.14	6,088.08
Less: Loss Allowance	(618.76)	(464.00)
<b>TOTAL</b>	<b>6,094.38</b>	<b>5,624.08</b>
<b>Note:</b> Above trade receivable includes amount due from related parties <b>Rs. 1858.35 Lakhs</b> (Previous year Rs.1708.48 Lakhs)		





**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**

**Trade receivable ageing schedule**  
**As at 31st March, 2025**

Particulars	Not Due	Outstanding for Following periods from due date of payment					Total
		Less than 6 Months	6 Months - 1 Year	1 Year - 2 Years	2 Years - 3 Years	More than 3 Years	
(i) Undisputed Trade Receivables – Considered Good	4,951.61	1,082.24	87.90	48.93	65.63	84.27	6,320.58
(ii) Undisputed Trade Receivables – Credit Impaired	-	164.79	28.41	-	-	-	193.20
(iii) Disputed Trade Receivables – Considered Good	-	3.19	26.65	22.97	103.70	42.85	199.36
<b>Total</b>	<b>4,951.61</b>	<b>1,250.22</b>	<b>142.96</b>	<b>71.90</b>	<b>169.33</b>	<b>127.12</b>	<b>6,713.14</b>
Less: Loss Allowance	-	-	-	-	-	-	618.76
<b>Net Total</b>	<b>4,951.61</b>	<b>1,250.22</b>	<b>142.96</b>	<b>71.90</b>	<b>169.33</b>	<b>127.12</b>	<b>6,094.38</b>

**As at 31st March, 2024**

Particulars	Not Due	Outstanding for Following periods from due date of payment					Total
		Less than 6 Months	6 Months - 1 Year	1 Year - 2 Years	2 Years - 3 Years	More than 3 Years	
(i) Undisputed Trade Receivables – Considered Good	3,546.57	2,072.12	120.53	175.90	31.97	75.53	6,022.62
(ii) Disputed Trade Receivables – Considered Good	-	-	-	16.30	14.11	35.05	65.46
<b>Total</b>	<b>3,546.57</b>	<b>2,072.12</b>	<b>120.53</b>	<b>192.22</b>	<b>46.08</b>	<b>110.57</b>	<b>6,088.09</b>
Less: Loss Allowance	-	-	-	-	-	-	464.00
<b>Net Total</b>	<b>3,546.57</b>	<b>2,072.12</b>	<b>120.53</b>	<b>192.22</b>	<b>46.08</b>	<b>110.57</b>	<b>5,624.08</b>

There are no unbilled receivables, hence the same is not disclosed in the ageing schedule.

**Relationship with struck off companies**

The Company does not have any transactions or balances with struck off Companies.

PARTICULARS	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.9 : CASH AND CASH EQUIVALENTS:</b>		
Cash on hand	0.93	3.69
Balance with banks:		
In current accounts	283.19	436.45
Bank deposits with original maturity not more than 3 months	1,009.16	-
<b>TOTAL</b>	<b>1,293.28</b>	<b>440.14</b>
<b>3.10 : BANK BALANCE OTHER THAN CASH &amp; CASH EQUIVALENTS :</b>		
Bank deposits with remaining maturity less than 12 months	6,442.84	7,891.41
Margin deposit	7.14	6.71
<b>TOTAL</b>	<b>6,449.98</b>	<b>7,898.12</b>



CACHET PHARMACEUTICALS PRIVATE LIMITED  
NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025

PARTICULARS	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.11 : CURRENT LOANS:</b>		
Loans and advances to employees		
<b>TOTAL</b>	<b>145.20</b>	<b>54.22</b>
	<b>145.20</b>	<b>54.22</b>
<b>Break-up of current loans:</b>		
Loans considered good - Secured	-	-
Loans considered good - Unsecured	-	-
Loans - credit impaired	145.20	54.22
<b>Total</b>	<b>48.22</b>	<b>18.56</b>
Less: Loss allowance	193.42	72.77
<b>Total current loans</b>	<b>(48.22)</b>	<b>(18.56)</b>
	<b>145.20</b>	<b>54.22</b>
<b>3.12 : OTHER CURRENT FINANCIAL ASSETS :</b>		
Interest on bonds, accrued but not due	53.44	2.72
Export incentives receivable	37.53	66.68
<b>TOTAL</b>	<b>90.97</b>	<b>69.40</b>
<b>3.13 : OTHER CURRENT ASSETS:</b>		
(Unsecured, considered good unless otherwise stated)		
Balances with government authorities	352.90	320.04
Advance to suppliers	50.22	80.57
Prepaid expenses	138.32	96.59
Other receivables	-	2.25
Right to return assets	191.13	525.42
<b>TOTAL</b>	<b>732.57</b>	<b>1,024.87</b>





Particulars	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.14 : EQUITY SHARE CAPITAL:</b>		
Authorised:		
40,000 (previous year: 40,000) equity shares of Rs.100/- each	40.00	40.00
	40.00	40.00
Issued, subscribed and paid up:		
17,834 (previous year: 17,834) equity shares of Rs.100/- each fully paid up	17.83	17.83
<b>TOTAL</b>	<b>17.83</b>	<b>17.83</b>

## (a) Reconciliation of the number of equity shares outstanding at the beginning and at the end of the year:

Particulars	As at 31st March, 2025	As at 31st March, 2024
At the commencement of the year	17,834	17,834
At the end of the year	17,834	17,834

## (b) Rights, preferences and restrictions attached to Equity Shares:

The Company has only one class of equity shares with voting rights having a par value of Rs. 100/- per share. Each shareholder is eligible for one vote per share held.

On winding up of the Company, the shareholders of equity shares will be entitled to receive residual assets of the Company remaining after distribution of all preferential amounts in proportion to the number of equity shares held by the shareholders.

## (c) Details of Holding Company:

Particulars	As at 31st March, 2025		As at 31st March, 2024	
	Percentage of Holding	Number of Shares	Percentage of Holding	Number of Shares
Alkem Laboratories Ltd.	60.63%	10,813	60.63%	10,813

## (d) Details of shareholders holding more than 5% shares in the Company:

Particulars	As at 31st March, 2025		As at 31st March, 2024	
	Percentage of Holding	Number of Shares	Percentage of Holding	Number of Shares
Alkem Laboratories Ltd. (The Holding Company)	60.63%	10,813	60.63%	10,813

## (e) Shareholding of Promoter:

As at 31st March, 2025

Promoter Name	No. of shares at the beginning of the year	Changes during the year	No. of Shares at the end of the year	% of total shares	% Change during the year
<b>Equity Shares:</b>					
Alkem Laboratories Ltd.	10,813	-	10,813	60.63%	0%
Ms. Madhurima Singh	890	-	890	4.99%	0%
Mr. Satish Kumar Singh	797	-	797	4.47%	0%
Ms. Prerana Kumar	758	-	758	4.25%	0%
Mr. Basudeo Narain Singh	731	-	731	4.10%	0%
Ms. Manju Singh	596	-	596	3.34%	0%
Ms. Anita Singh	585	-	585	3.28%	0%
Mr. Mritunjay Kumar Singh	525	-	525	2.94%	0%
Ms. Seema Singh	365	-	365	2.05%	0%
Mr. Sarvesh Singh	340	-	340	1.91%	0%
Mr. Sandeep Singh	340	-	340	1.91%	0%
Ms. Jayanti Sinha	233	-	233	1.31%	0%
Mr. Rajesh Kumar	225	-	225	1.26%	0%
Mr. Sarandhar Singh	168	-	168	0.94%	0%
Mr. Srinivas Singh	168	-	168	0.94%	0%
Ms. Archana Singh	150	-	150	0.84%	0%
Mr. Rajeev Ranjan	150	-	150	0.84%	0%
<b>Total</b>	<b>17,834</b>	<b>-</b>	<b>17,834</b>	<b>100.00%</b>	



**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**

As at 31st March, 2024

Promoter Name	No. of shares at the beginning of the year	Changes during the year	No. of Shares at the end of the year	% of total shares	% Change during the year
<b>Equity Shares:</b>					
Alkem Laboratories Ltd.	10,813	-	10,813	60.63%	0%
Ms. Madhurima Singh	365	525	890	4.99%	144%
Mr. Satish Kumar Singh	797	-	797	4.47%	0%
Ms. Prerana Kumar	758	-	758	4.25%	0%
Mr. Basudeo Narain Singh	731	-	731	4.10%	0%
Ms. Manju Singh	428	168	596	3.34%	39%
Ms. Anita Singh	585	-	585	3.28%	0%
Mr. Mritunjay Kumar Singh	525	-	525	2.94%	0%
Ms. Seema Singh	365	-	365	2.05%	0%
Mr. Sarvesh Singh	340	-	340	1.91%	0%
Mr. Sandeep Singh	340	-	340	1.91%	0%
Ms. Jayanti Sinha	233	-	233	1.31%	0%
Mr. Rajesh Kumar	225	-	225	1.26%	0%
Mr. Sarandhar Singh	-	168	168	0.94%	100%
Mr. Srinivas Singh	-	168	168	0.94%	100%
Ms. Archana Singh	150	-	150	0.84%	0%
Mr. Rajeev Ranjan	150	-	150	0.84%	0%
Mr. Dhananjay Kumar Singh	525	(525)	-	0.00%	100%
Mr. Balmiki Prasad Singh	504	(504)	-	0.00%	100%
<b>Total</b>	<b>17,834</b>	<b>-</b>	<b>17,834</b>	<b>100.00%</b>	<b>0.00%</b>

Particulars	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.15 : OTHER EQUITY:</b>		
<b>Capital reserve:</b>		
At the balance sheet date	31.00	31.00
<b>Securities premium account:</b>		
At the balance sheet date	2,496.70	2,496.70
<b>General reserve:</b>		
At the commencement of the year	2,500.00	2,500.00
Add: Transferred from Surplus in the Statement of Profit and Loss during the year	-	-
At the end of the year	2,500.00	2,500.00
<b>Retained Earning:</b>		
At the commencement of the year	3,446.66	2,620.14
Add: Profit after tax for the year	4,309.55	826.52
Profit available for appropriation	7,756.20	3,446.66
Less : Transfer to General Reserve	-	-
At the end of the year	7,756.20	3,446.66
<b>Other Comprehensive Income/(Loss):</b>		
Balance at the beginning of the year	(199.94)	(159.30)
Add: Profit after tax for the year	(121.27)	(40.64)
Balance at the end of the year	(321.21)	(199.94)
<b>TOTAL</b>	<b>12,462.69</b>	<b>8,274.42</b>





CACHET PHARMACEUTICALS PRIVATE LIMITED  
NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025

Particulars	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.16 : NON CURRENT LEASE LIABILITIES:</b>		
Lease liabilities (Refer Note 3.42)	296.13	140.92
<b>TOTAL</b>	<b>296.13</b>	<b>140.92</b>
<b>3.17 : NON CURRENT PROVISIONS:</b>		
Provisions for Employee Benefits:		
Gratuity (Refer Note 3.33)	1,200.53	1,055.57
Compensated absences	440.52	382.23
<b>TOTAL</b>	<b>1,641.05</b>	<b>1,437.80</b>
<b>3.18 : CURRENT BORROWINGS:</b>		
<u>Secured:</u>		
Working capital loans from bank	-	134.45
<b>TOTAL</b>	<b>-</b>	<b>134.45</b>
<u>Secured</u> Working capital loan comprises of Packing credit in Foreign currencies provided by ICICI Bank of Rs. NIL (31st March 2024: Rs. 134.45 Lakhs) are repayable on demand and it carries interest rate in the range of 4.50% to 6.32%, which are secured against hypothecation of company's stock, book debts, tangible movable property.		
<b>3.19 : CURRENT LEASE LIABILITIES:</b>		
Lease liabilities ( Refer Note 3.42 (ii) )	84.44	62.88
<b>TOTAL</b>	<b>84.44</b>	<b>62.88</b>
<b>3.20 : TRADE PAYABLES:</b>		
Total Outstanding Dues of micro and small enterprises ( Refer Note 3.32 )	311.81	339.58
Total Outstanding Dues of creditors other than micro and small enterprises*	6,107.04	5,422.76
<b>TOTAL</b>	<b>6,418.85</b>	<b>5,762.34</b>

\*Above trade payable includes amount due to related parties **Rs. 85.66 Lakhs** (Previous year Rs. 72.34 Lakhs) (Refer Note 3.37)



**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025**

**Trade Payable ageing schedule**  
**As at 31st March, 2025**

Particulars	Unbilled	Not due	Outstanding for Following periods from the due date of payment				Total
			Less than 1 Year	1 to 2 Years	2 to 3 Years	More than 3 Years	
(i) MSME	-	282.61	29.20	-	-	-	311.81
(ii) Others	1,085.19	4,247.89	722.15	0.49	0.30	51.02	6,107.04
<b>Total</b>	<b>1,085.19</b>	<b>4,530.50</b>	<b>751.35</b>	<b>0.49</b>	<b>0.30</b>	<b>51.02</b>	<b>6,418.85</b>

**As at 31st March, 2024**

Particulars	Unbilled	Not due	Outstanding for Following periods from the due date of payment				Total
			Less than 1 Year	1 to 2 Years	2 to 3 Years	More than 3 Years	
(i) MSME	-	326.76	12.82	-	-	-	339.58
(ii) Others	1,059.82	4,157.97	153.53	0.34	0.11	50.99	5,422.76
<b>Total</b>	<b>1,059.82</b>	<b>4,484.73</b>	<b>166.35</b>	<b>0.34</b>	<b>0.11</b>	<b>50.99</b>	<b>5,762.34</b>

Particulars	As at 31st March, 2025	As at 31st March, 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.21 : OTHER CURRENT FINANCIAL LIABILITIES:</b>		
Security deposits		
Employee payables	419.00	459.00
Liability towards Anticipated Sales Returns ( Refer Note No. 3.35 ( ii ) )	2,015.66	2,449.83
	1,409.60	1,876.64
<b>TOTAL</b>	<b>3,844.26</b>	<b>4,785.47</b>
<b>3.22 : OTHER CURRENT LIABILITIES:</b>		
Advances from customers		
Deferred income on charges recovery	412.65	356.18
Due to statutory authorities*	-	2.00
	356.88	326.72
<b>TOTAL</b>	<b>769.53</b>	<b>684.90</b>
*Due to statutory authorities includes GST payable, tax deducted at source payable, tax collected at source payable, provident fund and other funds payable.		
<b>3.23 : CURRENT PROVISIONS:</b>		
Provision for employee benefits:		
Gratuity (Refer Note 3.33)		
Compensated absences	107.04	147.53
	111.11	102.72
<b>TOTAL</b>	<b>218.15</b>	<b>250.25</b>





Particulars	For the year ended 31st March 2025	For the year ended 31st March 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.24 : REVENUE FROM OPERATIONS:</b>		
Refer Note 3.35 ( i )		
<u>Revenue from contracts with customers:</u>		
Sale of products	45,220.08	43,525.66
<u>Other operating revenue:</u>		
Manufacturing charges	554.10	558.44
Export incentives	124.92	119.32
Royalty Income	2.69	3.62
Scrap sales	34.25	36.59
<b>TOTAL</b>	<b>45,936.04</b>	<b>44,243.63</b>
<b>3.25 : OTHER INCOME:</b>		
Interest income under Effective interest method		
- Bank deposits at amortised cost	765.56	560.17
- Bonds, Debentures and loans at amortised cost	38.65	5.65
Provisions written back	927.71	-
Dividend income	0.22	0.22
Insurance claim	0.27	0.09
Miscellaneous income/ receipts	16.93	17.10
Profit on sale of property, plant and equipments (net)	0.66	-
Realized gain on Mutual Fund	-	0.89
Unrealized gain on Mutual Fund	13.00	9.23
Foreign currency transactions and translation gain (net)	102.69	70.71
<b>TOTAL</b>	<b>1,865.69</b>	<b>664.06</b>
<b>3.26 : COST OF MATERIALS CONSUMED:</b>		
Raw material consumed	2,884.67	2,778.50
Packing material consumed	1,615.29	1,512.43
<b>TOTAL</b>	<b>4,499.96</b>	<b>4,290.93</b>
<b>3.27 : CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE:</b>		
Opening stock:		
Finished goods	427.67	541.25
Stock-in-trade	1,249.76	1,555.61
Work-in-progress	48.81	61.11
	<b>1,726.24</b>	<b>2,157.97</b>
Less: Closing Stock		
Finished goods	409.92	427.67
Stock-in-trade	1,207.14	1,249.76
Work-in-progress	87.48	48.81
	<b>1,704.54</b>	<b>1,726.24</b>
<b>TOTAL</b>	<b>21.70</b>	<b>431.73</b>
<b>3.28 : EMPLOYEE BENEFITS EXPENSE:</b>		
Salaries, wages and bonus	8,913.88	8,778.59
Contribution to provident and other funds ( Refer Note 3.33 )	472.43	468.69
Employees' welfare expenses	127.52	111.08
<b>TOTAL</b>	<b>9,513.83</b>	<b>9,358.36</b>
<b>3.29 : FINANCE COST:</b>		
Interest on borrowings	37.92	25.71
Interest on lease liabilities ( Refer Note 3.42 ( iii ) )	22.42	19.47
Interest on defined benefit liabilities ( Refer Note 3.33 )	76.16	75.38
Other borrowing cost	12.71	10.91
<b>TOTAL</b>	<b>149.21</b>	<b>131.47</b>



Particulars	For the year ended 31st March 2025	For the year ended 31st March 2024
	Rs. in Lakhs	Rs. in Lakhs
<b>3.30 : OTHER EXPENSES:</b>		
Consumption of stores and spare parts	57.95	45.38
Power and fuel	315.03	275.58
Rent ( Refer Note 3.42 ( iii ) )	39.13	41.59
Rates and taxes	343.95	588.75
Insurance	149.75	151.72
Commission to C&F agents	211.38	212.77
Freight and distribution expenses	925.07	861.20
Marketing expenses	2,181.05	2,295.52
Travelling and conveyance	1,929.36	2,009.22
Repairs:		
- Buildings	73.20	54.54
- Plant and machineries	70.71	91.58
- Others	64.51	59.39
Loss on sale of property, plant and equipments	-	1.26
Legal and professional fees	270.16	254.27
Allowance for doubtful debts	154.75	59.80
Contract labour charges	391.37	331.76
Miscellaneous expenses	792.03	956.18
Corporate Social Responsibility expense ( Refer Note 3.39 )	46.65	30.51
<b>TOTAL</b>	<b>8,016.05</b>	<b>8,321.01</b>





3.31 Contingent liabilities and commitments

a) Contingent liabilities

Sr. No.	Particulars	(Rs. in Lakhs)	
		As at 31st March, 2025	As at 31st March, 2024
	<b>Claims against the Company not acknowledged as debt:</b>		
(i)	Cenvat credit disputed with GST Appellate Tribunal (yet to be constituted) for FY 2017-18 (Advances paid in dispute Rs. 0.61 Lakhs)	2.02	2.02
(ii)	Custom Duty demand disputed with Assistant Commissioner of Customs Drawback Recovery Cell for FY 14-15 till FY 17-18 (Advances paid in dispute Rs. Nil)	24.31	24.31
(iii)	Income Tax demand disputed in appeal for AY 2015-16 (Advance paid in dispute of Rs. 3 Lakhs)	10.58	10.58
(iv)	Income Tax demand disputed by rectification petition before assessing officer for AY 2012-13 (Other refund of Rs.6.29 Lakhs has been adjusted)	-	6.29
(v)	Income Tax demand disputed by rectification petition before Assessing Officer for AY 2016-17 (Other refund of Rs.14.65 Lakhs has been adjusted)	-	14.65
(vi)	Income Tax demand disputed by rectification petition before Assessing Officer for AY 2021-22 (Other refund of Rs.3.42 Lakhs has been adjusted)	-	7.43
	<b>Total</b>	<b>36.91</b>	<b>65.28</b>

Management considers that the above demands received from the respective authorities are not tenable against the Company, and therefore no provision for these tax contingencies have been made.

The Company has reviewed all its pending litigations and proceedings and has adequately provided for, where provisions are required and disclosed as contingent liabilities wherever applicable, in its financial statement. The Company does not expect the outcome of these proceedings to have materially adverse effect on its financial statements.

b) Commitments

Sr. No.	Particulars	(Rs. in Lakhs)	
		As at 31st March, 2025	As at 31st March, 2024
1	Estimated amount of contracts remaining to be executed on Capital Accounts - advance paid Rs. 3.10 Lakhs (Previous Year Rs.1.75 Lakhs)	14.96	95.64
	<b>Total</b>	<b>14.96</b>	<b>95.64</b>

3.32 Dues to Micro and Small Enterprises

Under the Micro, Small and Medium Enterprises Development Act, 2006, (MSMED), certain disclosures are required to be made relating to Micro and Small Enterprises. On the basis of the information and records available with the Management, the outstanding dues to the Micro & Small Enterprises as defined in MSMED are set out in following disclosure:

Sr. No.	Particulars	(Rs. in Lakhs)	
		As at 31st March, 2025	As at 31st March, 2024
a	Principal amount remaining unpaid to any supplier as at the year end	311.81	339.58
b	Interest due thereon	0.03	0.02
c	Amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond appointed day during each accounting year.	-	-
d	The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006.	-	-
e	The amount of interest accrued and remaining unpaid at the end of each accounting year.	0.03	0.02
f	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-	-



**3.33 Disclosure of Employee Benefits as per Indian Accounting Standard 19 is as under:**

**i) Defined contribution plans:**

The Company makes contributions towards provident fund to a defined contribution retirement benefit plan for qualifying employees. Under the plan, the Company is required to contribute a specified percentage of salary cost to the retirement benefit plan to fund the benefits. The provident fund plan and Employee State Insurance Corporation plan is operated by the Government administered. Eligible employees receive the benefits from the said Provident Fund and Employee State Insurance Corporation. Both the employees and the Company make monthly contribution to the Provident Fund and Employee State Insurance Corporation equal to a specific percentage of the covered employee's salary. The Company has no obligations other than to make the specified contributions.

The Company has recognised the following amounts in the statement of Profit and Loss:

Particulars	(Rs. in Lakhs)	
	As at 31st March, 2025	As at 31st March, 2024
Contribution to Provident Fund and Other Funds	435.54	427.46
Contribution to Employees State Insurance Corporation	36.89	41.10
<b>Total</b>	<b>472.43</b>	<b>468.56</b>

**ii) Defined benefit plan:**

The Company has made partial amount of contribution towards Employees Gratuity Trust and also earmarks the balance liability towards gratuity and provides for payment to vested employees as under:

a) On Normal retirement/ early retirement/ withdrawal/ resignation:

As per the provisions of Payment of Gratuity Act, 1972 with vesting period of 5 years of service.

b) On death in service:

As per the provisions of Payment of Gratuity Act, 1972 without any vesting period.

The most recent actuarial valuation of the present value of the defined benefit obligation for gratuity was carried out as at 31st March, 2025 by an independent actuary. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

The following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at 31st March 2025:

Sr. No.	Particulars	(Rs. in Lakhs)	
		As at 31st March, 2025	As at 31st March, 2024
I)	<b>Reconciliation in present value of obligations (PVO) – defined benefit obligation :</b>		
	Current Service Cost		
	Past Service Cost	101.54	88.42
	Interest Cost	-	163.42
	Actuarial (gain) / losses	86.47	75.38
	Benefits paid	160.69	57.46
	PVO at the beginning of the year	(121.71)	(167.15)
	PVO at end of the year	1,346.26	1,128.73
II)	<b>Reconciliation of PVO and fair value of plan assets:</b>	1,573.25	1,346.26
	Opening Value of Plan Asset		
	Actuarial gain/(losses) on plan assets	143.16	-
	Contribution towards plan assets	(1.38)	3.16
	Unrecognised actuarial gain/ (loss)	150.00	140.00
	Refund from Fund	10.31	-
	Net asset/ (liability) recognised in the balance sheet	(36.40)	-
III)	<b>Net cost for the year</b>	(1,307.56)	(1,203.10)
	Current Service cost		
	Interest cost	101.54	88.42
	Expected return on plan assets	86.47	75.38
	Actuarial (gain) / losses	(10.31)	-
	<b>Net cost</b>	162.07	54.31
IV)	<b>Assumption used in accounting for the gratuity plan:</b>	339.77	218.11
	Discount rate (%)	6.67%	7.20%
	Mortality Rate	Indian Assured Lives Mortality (2012-14) Ultimate	Indian Assured Lives Mortality (2012-14) Ultimate
	Salary escalation rate (%)	9% for 1st year, 5% thereafter	9% for 1st year, 5% thereafter





NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025

**Discount rate:** The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

**Salary Escalation Rate:** The estimates of future salary increases, considered in actuarial valuation, takes into account the inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

**Maturity profile of Defined benefit obligation:**

Projected benefits payable in future years from the date of reporting	(Rs. in Lakhs)	
	As at 31st March, 2025	As at 31st March, 2024
1 <sup>st</sup> following year	372.72	290.69
2 <sup>nd</sup> following year	189.17	183.26
3 <sup>rd</sup> following year	212.96	149.70
4 <sup>th</sup> following year	226.68	190.94
5 <sup>th</sup> following year	138.74	181.80
Sum of years 6 <sup>th</sup> to 10 <sup>th</sup>	531.01	472.22
Sum of years 11 <sup>th</sup> and above	650.86	597.22

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below:

Particulars	31st March, 2025		31st March, 2024	
	Increase	Decrease	Increase	Decrease
Discount rate (1% movement)	(70.90)	78.67	(81.93)	210.97
Future salary growth (1% movement)	86.47	(79.28)	211.53	(80.36)

The mortality and attrition does not have a significant impact on the liability, hence are not considered a significant actuarial assumptions for the purpose of sensitivity analysis.



3.34 Earnings per share (EPS)

Particulars			For the year ended 31st March, 2025	For the year ended 31st March, 2024
Profit/(loss) after tax attributable to equity shareholders	Rs. in Lakhs	A	4,309.55	826.52
Weighted average number of equity shares outstanding	Nos.	B	17,834	17,834
Earnings Per Share - Basic and Diluted ( face value Rs.100/-)	INR	(A / B)	24,164.78	4,634.51

3.35 Disclosure as per Ind AS 115 'Revenue from Contracts with Customers' is as under :

- i Reconciliation of the amount of revenue recognised in the statement of profit and loss with the contracted price:

Particulars			(Rs. in Lakhs)	
			For the year ended 31st March, 2025	For the year ended 31st March, 2024
Revenue from contract with Customers as per contracted price - Sale of products and manufacturing charges			45,301.25	44,154.28
Adjustments made to contract price on account of :				
Less : Sales return			467.04	(74.83)
Less : Discounts			(0.00)	(0.02)
Add : Ind AS 21 (Appendix B) - Advance consideration			5.90	4.67
Revenue from contract with customers			45,774.19	44,084.10
Other operating revenue (other than manufacturing charges)			161.85	159.53
Revenue from operations			45,936.04	44,243.63

ii Liabilities towards anticipated sales return :

The Company as a trade practice, accepts sales return from market which are primarily in the nature of expired or near expiry products. Liability is created for such returns on the basis of historical experience, market conditions and specific contractual terms. The company expects to settle the majority of the liability towards saleable return over the next year and towards non saleable return over the next two years.

Particulars			(Rs. in Lakhs)	
			For the year ended 31st March, 2025	For the year ended 31st March, 2024
Carrying amount at the beginning of the year			1,876.64	1,801.81
Add: Provision made during the year			960.95	921.06
Less: Amount utilized during the year			1,427.99	846.23
Carrying amount at the end of the year			1,409.60	1,876.64

3.36 Segment Reporting

The operations of the Company is limited to one segment viz. Pharmaceutical and related products. The products being sold under this segment are of a similar nature and comprises of pharmaceuticals products only.

Entity-wide disclosures

The geographical segment revenues by the companies country of domicile (i.e. India) and other countries are as under :

Sr. No.		Particulars	(Rs. in Lakhs)	
			For the year ended 31st March, 2025	For the year ended 31st March, 2024
a)		Revenues from sale of products from external customers attributed to the country of domicile and attributed to all foreign countries from which the company derives revenues		
		Revenue from the Country of Domicile - India	37,959.71	37,026.53
		Revenue from sale of service from the Country of Domicile - India	554.10	558.44
		Revenue from foreign countries	7,422.23	6,658.66
		Total	45,936.04	44,243.63
b)		Revenue from sale of products to a customer (including group entities, excluding taxes), which is more than 10% of the total revenue from India		
		Alkem Laboratories Limited	13,583.76	12,530.42
		Total	13,583.76	12,530.42





3.37 Information on related party transactions as required by Indian Accounting Standard 24 (Ind AS 24) on related party disclosures

A. List of related parties and their relationship

I Key Managerial Personnel (KMP) :

Name of the KMP	Designation
Mr. Satish Kumar Singh	Managing Director
Mrs. Premilata Singh	Director
Mr. Arunkumar Deshmukh	Independent Director
Dr.(Mrs.) Anuja Madhurendra Sinha	Independent Director

II Close Members of Key Managerial Personnel (K.M.P.) with whom transactions have taken place during the year:

Name of the close member of KMP	Relation
Mr. Sanjay Kumar	Brother of Mrs. Premilata Singh

Entity in which Key Managerial Personnel's and their close members have significant influence and with whom transactions have taken place during the year ("Affiliate"):

M/s Galpha Laboratories Ltd.

III Holding Company:

Name of the Company	Country of Incorporation
Alkem Laboratories Ltd.	India

IV Fellow Subsidiary Companies:

Name of the Companies	Country of Incorporation
Pharmacor Pty Limited	Australia
Ascend Laboratories Ltd.	Canada
Ascend Laboratories SpA	Chile
Pharma Network SpA (Wholly owned by Ascend Laboratories SpA)	Chile
Ascend Laboratories SAS	Colombia
Ascend GmbH (formerly known as Alkem Pharma GmbH)	Germany
Alkem Foundation	India
Alixer Nexgen Therapeutics Limited (w.e.f. 12th July, 2024 )	India
Alkem Wellness Limited (w.e.f. 16th September, 2024)	India
Connect 2 Clinic Private Limited	India
Enzene Biosciences Ltd.	India
Indchemie Health Specialities Pvt. Ltd.	India
The PharmaNetwork, LLP	Kazakhstan
Pharmacor Ltd.	Kenya
Ascend Laboratories SDN BHD.	Malaysia
Alkem Laboratories Korea Inc.	South Korea
S&B Holdings S.a.r.l. (Previously known as S&B Holdings B.V with principle place of business based at Netherlands redomiciled to Luxembourg w.e.f 16 Oct 2023).	Luxembourg
Alkem Laboratories Corporation	Philippines
Ascend Laboratories S.A. DE C.V. (Wholly owned by Ascend Laboratories SpA)	Mexico
Ascend Laboratories (PTY) Limited (formerly known as Alkem Laboratories (PTY) Limited)	South Africa
Ascend Laboratories (UK) Ltd.	United Kingdom
Ascend Laboratories, LLC (Wholly owned by ThePharmaNetwork, LLC)	United States of America
S & B Pharma LLC (Wholly owned by ThePharmaNetwork, LLC)	United States of America
ThePharmaNetwork, LLC (subsidiary of S & B Holdings S.a.r.l.)	United States of America
Enzene Inc (wholly owned by Enzene Bioscience Ltd. w.e.f. 26th May 2022)	United States of America
Pharmacor Ltd. (wholly owned subsidiary of Pharmacor Pty Ltd. w.e.f. 1st June 2022)	New Zealand
Alkem Medtech Private Limited (w.e.f. 27th March, 2024)	India
Pharmacor SpA (Wholly owned subsidiary of Pharmacor Pty Limited, Australia)	Chile



B. Details of Transactions with Related Parties

(Rs. in Lakhs)

Sr. No.	Particulars	For the year ended 31st March, 2025					
		Key Managerial Personnel	Close members of Key Managerial Personnel	Holding Company	Fellow Subsidiaries	Affiliate	Total
		A	B	C	D	E	
1	Remuneration	-	116.09	-	-	-	116.09
			(101.54)	-	-	-	(101.54)
2	Director sitting fees	1.80	-	-	-	-	1.80
		(1.72)	-	-	-	-	(1.72)
3	Advance given	-	26.50	-	-	-	26.50
		-	-	-	-	-	-
4	Purchase of finished goods	-	-	-	744.23	111.61	855.84
		-	-	-	(881.21)	(130.45)	(1,011.65)
5	Purchase of raw materials and packing materials	-	-	0.31	-	0.29	0.60
		-	-	(0.30)	-	-	(0.30)
6	Sale of finished goods	-	-	15,236.48	-	-	15,236.48
		-	-	(14,481.32)	-	-	(14,481.32)
7	Sale of raw materials and packing materials	-	-	-	-	-	-
		-	-	(0.69)	-	-	(0.69)
8	Royalty income	-	-	3.17	-	-	3.17
		-	-	(4.27)	-	-	(4.27)
9	Rendering of services	-	-	649.08	-	-	649.08
		-	-	(659.69)	-	-	(659.69)
10	Payment of rent	-	-	49.21	-	-	49.21
		-	-	(49.21)	-	-	(49.21)
11	Recovery of expenses (net)	-	-	50.19	-	1.48	51.67
		-	-	-	-	-	-
12	Reimbursement of expenses (net)	-	-	-	1.88	-	1.88
		-	-	(1.11)	(1.05)	-	(2.16)

Figures in the brackets are corresponding figures of previous year.

C. Balance due from/ to the related parties

(Rs. in Lakhs)

Sr. No.	Particulars	As at 31st March, 2025					
		Key Managerial Personnel	Close members of Key Managerial Personnel	Holding Company	Fellow Subsidiaries	Affiliate	Total
1	Security deposit receivable	-	-	9.57	-	-	9.57
2	Outstanding receivable	-	26.50	1,818.45	-	-	1,844.95
3	Outstanding payable	-	-	-	48.82	36.84	85.66

(Rs. in Lakhs)

Sr. No.	Particulars	As at 31st March, 2024					
		Key Managerial Personnel	Close members of Key Managerial Personnel	Holding Company	Fellow Subsidiaries	Affiliate	Total
1	Security deposit receivable	-	-	9.57	-	-	9.57
2	Outstanding receivable	-	-	1,708.48	-	-	1,708.48
3	Outstanding payable	-	-	-	34.15	50.56	84.71

All the above related party transactions are made in the normal course of business and on terms equivalent to those that prevail in an arm's length transactions.





3.38 Payment to auditors (excluding GST)

(Rs. in Lakhs)

Particulars	For the year ended 31st March, 2025	For the year ended 31st March, 2024
<b>As auditor:</b>		
Audit fees	13.75	13.75
Tax audit fees	5.00	5.00
<b>In other capacity:</b>		
For Taxation Matters	12.00	-
<b>Total</b>	<b>30.75</b>	<b>18.75</b>

3.39 Details of Corporate Social Responsibility (CSR) expenditure :

(Rs. in Lakhs)

Sr no	Particulars	For the year ended 31st March, 2025	For the year ended 31st March, 2024
a)	Amount required to be spent by the Company during the year	46.57	30.51
b)	Amount of expenditure incurred	46.65	30.51
c)	Shortfall/(Excess)	(0.08)	-

d)	<b>Nature of CSR activities</b>
	<p><b>Financial Year-2024-2025</b></p> <p>The Company has spent an amount of 46.65 Lakh towards the CSR obligation. The Company has contributed Rs 46.00 Lakh to "Prime Minister's National Relief Fund (PMNRF)", with the main objectives to render immediate relief to families of those killed in natural calamities like floods, cyclones and earthquakes, etc. and to the victims of the major accidents and riots. Assistance from PMNRF is also rendered, to partially defray the expenses for medical treatment like heart surgeries, kidney transplantation, cancer treatment and acid attack etc. The fund is recognized as a Trust under the Income Tax Act and the same is managed by Prime Minister or multiple delegates for national causes.</p>
	<p><b>Financial Year-2023-2024</b></p> <p>The Company has spent an amount of 30.51 Lakh towards the CSR obligation. The Company has contributed Rs 30.51 Lakh to "Prime Minister's National Relief Fund (PMNRF)", with the main objectives to render immediate relief to families of those killed in natural calamities like floods, cyclones and earthquakes, etc. and to the victims of the major accidents and riots. Assistance from PMNRF is also rendered, to partially defray the expenses for medical treatment like heart surgeries, kidney transplantation, cancer treatment and acid attack etc. The fund is recognized as a Trust under the Income Tax Act and the same is managed by Prime Minister or multiple delegates for national causes.</p>



3.40 Financial Instruments – Fair values and risk management

A Accounting classification and fair values

The Company uses the following hierarchic structure of valuation methods to determine and disclose information about the fair value of financial instruments:

Level 1: Observable prices in active markets for identical assets and liabilities;

Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities;

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

(Rs. in Lakhs)

Particulars	As at 31st March, 2025							
	Carrying amount				Fair value			
	FVTPL	FVTOCI	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
<b>Financial assets</b>								
Cash and cash equivalents	-	-	1,293.28	1,293.28	-	-	-	-
Other bank balances	-	-	6,449.98	6,449.98	-	-	-	-
Non-current investments	1.15	-	944.66	945.81	-	-	1.15	1.15
Other non-current financial asset	-	-	3,746.08	3,746.08	-	-	-	-
Current financial assets - Loans	-	-	145.20	145.20	-	-	-	-
Trade and other receivables	-	-	6,094.38	6,094.38	-	-	-	-
Current Investments	257.25	-	49.92	307.17	257.25	-	-	257.25
Other current financial asset	-	-	90.96	90.96	-	-	-	-
	<b>258.40</b>	<b>-</b>	<b>18,814.46</b>	<b>19,072.86</b>	<b>257.25</b>	<b>-</b>	<b>1.15</b>	<b>258.40</b>
<b>Financial liabilities</b>								
Current financial liabilities - Borrowings	-	-	-	-	-	-	-	-
Trade and other payables	-	-	6,418.85	6,418.85	-	-	-	-
Non-current lease liabilities	-	-	296.13	296.13	-	-	-	-
Current lease liabilities	-	-	84.44	84.44	-	-	-	-
Other current financial liabilities	-	-	3,844.26	3,844.26	-	-	-	-
	<b>-</b>	<b>-</b>	<b>10,643.68</b>	<b>10,643.68</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

(Rs. in Lakhs)

Particulars	As at 31st March, 2024							
	Carrying amount				Fair value			
	FVTPL	FVTOCI	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
<b>Financial assets</b>								
Cash and cash equivalents	-	-	440.14	440.14	-	-	-	-
Other bank balances	-	-	7,898.12	7,898.12	-	-	-	-
Non-current investments	1.15	-	64.75	65.90	-	-	1.15	1.15
Other non-current financial asset	-	-	1,067.47	1,067.47	-	-	-	-
Current financial assets - Loans	-	-	54.22	54.22	-	-	-	-
Trade and other receivables	-	-	5,624.08	5,624.08	-	-	-	-
Current Investments	144.25	-	10.05	154.30	144.25	-	-	144.25
Other current financial asset	-	-	69.40	69.40	-	-	-	-
	<b>145.40</b>	<b>-</b>	<b>15,228.23</b>	<b>15,373.63</b>	<b>144.25</b>	<b>-</b>	<b>1.15</b>	<b>145.40</b>
<b>Financial liabilities</b>								
Current financial liabilities - Borrowings	-	-	134.45	134.45	-	-	-	-
Trade and other payables	-	-	5,762.35	5,762.35	-	-	-	-
Non-current lease liabilities	-	-	140.92	140.92	-	-	-	-
Current lease liabilities	-	-	62.88	62.88	-	-	-	-
Other current financial liabilities	-	-	4,785.47	4,785.47	-	-	-	-
	<b>-</b>	<b>-</b>	<b>10,886.07</b>	<b>10,886.07</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.





**i. Credit risk**

Credit risk is the risk of financial loss to the Company if a customer or counter party to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investments in debt securities.

The carrying amount of following financial assets represents the maximum credit exposure:

**Trade and other receivables**

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk of the industry and country in which customers operate.

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of trade and other receivables.

At March 31, 2025, the maximum exposure to credit risk for trade and other receivables by geographic region was as follows:

Particulars	(Rs. in Lakhs)	
	For the year ended 31st March, 2025	For the year ended 31st March, 2024
India	3,844.40	4,110.96
Other regions	2,249.98	1,513.12
<b>Total</b>	<b>6,094.38</b>	<b>5,624.08</b>

At 31st March, 2025, the Company had exposure to only one type of counter party.

At 31st March, 2025, the carrying amount of Company's most significant customer is Rs. 1,818.45 lakhs (Previous year Rs. 1,708.48 lakhs).

**Impairment**

At 31st March, 2025, the ageing of trade and other receivables that were not impaired was as follows:

Particulars	(Rs. in Lakhs)	
	For the year ended 31st March, 2025	For the year ended 31st March, 2024
Not past due	4,902.09	3,546.57
Past due 1-180 days	1,101.60	2,072.11
Past due more than 180 days	90.68	5.40
<b>Total</b>	<b>6,094.38</b>	<b>5,624.08</b>

Management believes that the unimpaired amounts that are past due by more than 180 days are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk, including underlying customers' credit ratings if they are available.

The movement in the allowance for impairment in respect of trade and other receivables during the year was as follows:

Particulars	31st March, 2025		31st March, 2024	
	Individual impairments	Collective impairments	Individual impairments	Collective impairments
Balance as at beginning of the year	-	464.00	-	403.70
Add: Impairment loss recognised	193.20	(38.44)	-	60.30
Less: Amounts written off	-	-	-	-
<b>Balance at the end of the year</b>	<b>193.20</b>	<b>425.56</b>	<b>-</b>	<b>464.00</b>

**ii. Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.



**Exposure to liquidity risk**

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.

(Rs. in Lakhs)

Particulars	Contractual cash flows - 31 March, 2025						
	Carrying amount	Total	2 months or less	2-12 months	1-2 years	2-5 years	More than 5 years
<b>Non-derivative financial liabilities</b>							
Trade and other payables	6,418.85	6,418.85	6,418.85	-	-	-	-
Non-current borrowings & lease liabilities	296.13	333.88	-	-	113.08	220.80	-
Current borrowings & lease liabilities	84.44	111.03	18.99	92.04	-	-	-
Other current financial liabilities	3,844.26	3,844.26	2,015.66	801.80	607.80	419.00	-

(Rs. in Lakhs)

Particulars	Contractual cash flows - 31 March, 2024						
	Carrying amount	Total	2 months or less	2-12 months	1-2 years	2-5 years	More than 5 years
<b>Non-derivative financial liabilities</b>							
Trade and other payables	5,762.35	5,762.35	5,762.35	-	-	-	-
Non-current borrowings & lease liabilities	140.92	157.91	-	-	52.20	105.71	-
Current borrowings & lease liabilities	197.33	210.41	152.65	57.75	-	-	-
Other current financial liabilities	4,785.47	4,785.47	2,449.83	1,257.04	619.60	459.00	-

**iii. Market risk**

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk. Thus, our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

**Currency risk**

The Company is exposed to currency risk on account of its borrowings, other payables, receivables and loans and advances in foreign currency. The functional currency of the Company is Indian Rupee. The Company has exposure to USD and EURO. The Company has not hedged this foreign currency exposure.

**Exposure to currency risk**

The currency profile of financial assets and financial liabilities as at 31st March, 2025 and 31st March, 2024 are as below:

Particulars	March 31, 2025	
	EURO in Lakh	USD in Lakh
Financial assets		
Trade and other receivables	2.04	23.07
Net Financial Asset/ (Liabilities)	2.04	23.07

Particulars	March 31, 2024	
	EURO in Lakh	USD in Lakh
Financial assets		
Trade and other receivables	2.84	17.25
Net Financial Asset/ (Liabilities)	2.84	17.25

The following significant exchange rates have been applied during the year:

Particulars	Year-end spot rate (INR)	
	March 31, 2025	March 31, 2024
EURO	92.09	89.94
USD	85.48	83.34





**Sensitivity analysis**

A reasonably possible strengthening (weakening) of the Indian Rupee against various foreign currencies at 31st March would have affected the measurement of financial instruments denominated in foreign currencies and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

(Rs. in Lakhs)

Effect in INR	Profit or loss		Equity, net of tax	
	Strengthening	Weakening	Strengthening	Weakening
31st March, 2025				
10% movement in foreign currencies				
EURO	18.75	(18.75)	14.03	(14.03)
USD	197.21	(197.21)	147.57	(147.57)
<b>Total</b>	<b>215.96</b>	<b>(215.96)</b>	<b>161.60</b>	<b>(161.60)</b>

(Rs. in Lakhs)

Effect in INR	Profit or loss		Equity, net of tax	
	Strengthening	Weakening	Strengthening	Weakening
31st March, 2024				
10% movement in foreign currencies				
EURO	25.51	(25.51)	19.09	(19.09)
USD	143.72	(143.72)	107.55	(107.55)
<b>Total</b>	<b>169.23</b>	<b>(169.23)</b>	<b>126.64</b>	<b>(126.64)</b>

**Interest rate risk**

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in the interest rates. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing investments will fluctuate because of fluctuations in the interest rates.

**Exposure to interest rate risk:**

Company's interest rate risk arises from borrowings and fixed income securities. Fixed income securities exposes the Company to fair value interest rate risk. The interest rate profile of the Company's interest-bearing financial instruments as reported to the management of the Company is as follows:

(Rs. in Lakhs)

Particulars	Carrying amount	
	March 31, 2025	March 31, 2024
<b>Fixed-rate instruments</b>		
Financial assets	11,335.84	9,094.61
Financial liabilities	380.57	338.25
<b>Total</b>	<b>10,955.27</b>	<b>8,756.36</b>

**Fair value sensitivity analysis for fixed-rate instruments**

The Company does not account for any fixed-rate financial assets or financial liabilities at fair value through profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

A change of 100 basis points in interest rates would not have any material impact on the equity.

As there are no variable rate instruments with the Company, disclosure requirement in relation to Sensitivity analysis is not applicable.



### 3.41 Capital management:

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital.

The Company monitors capital using a ratio of 'net debt' to 'total equity'. For this purpose, net debt is defined as total liabilities, comprising interest-bearing loans and borrowings and obligations under finance leases, less cash and cash equivalents. Total equity comprises all components of equity.

The Company's net debt to total equity ratio was as follows:

Particulars	Rs. in Lakhs	
	As at 31st March, 2025	As at 31st March, 2024
Total borrowings	-	134.45
Less: Cash and cash equivalents	1,293.28	440.14
Net debt	-	-
Total equity	12,480.52	8,292.25
Net debt to equity ratio	-	-

### 3.42 Leases (Ind AS 116)

The Company has adopted Ind AS 116 "Leases" with a date of initial application on 1 April 2019. As a result, the Company had changed its accounting policy for lease contracts. The Company applied Ind AS 116 using the modified retrospective approach and recognized lease liability equal to the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate at the date of initial application. The Company recognized a right of use asset at the date of initial application at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the balance sheet immediately before the date of initial application.

In the context of initial application, the Company has exercised the option not to apply the new recognition requirements to short-term leases and to leases of low-value asset.

#### A. Leases as lessee

##### i. Right-of-use assets

Right-of-use assets related to leased properties that do not meet the definition of investment property are presented as property, plant and equipment.

(Rs. in Lakhs)

Particulars	Buildings	
	As at 31st March, 2025	As at 31st March, 2024
Balance at commencement of the year	188.46	218.06
Amortization charge for the year	(84.30)	(90.18)
Additions to right-of-use assets	258.59	82.02
Adjustment to right-of-use assets	-	-
Deletion of right-of-use assets	(3.86)	(21.44)
Balance at end of the year	358.89	188.46

##### ii. Lease liability

(Rs. in Lakhs)

Particulars	Buildings	
	As at 31st March, 2025	As at 31st March, 2024
<b>Maturity analysis of lease liability - undiscounted contractual cash flows</b>		
Less than one year	111.03	75.96
One to three years	227.22	105.24
More than three years	106.66	52.67
<b>Total discounted cash flows</b>	<b>444.91</b>	<b>233.87</b>
Current ( Discounted )	84.44	62.88
Non-current ( Discounted )	296.13	140.92





iii. Amount recognised in profit or loss

Particulars	(Rs. in Lakhs)	
	For the year ended 31st March 2025	For the year ended 31st March 2024
<b>General and administrative expenses</b>		
Short-term lease rent expense	39.13	41.59
Other Income	(1.28)	(0.38)
<b>Amortisation and impairment losses</b>		
Amortisation of right of use asset	84.30	90.18
<b>Finance cost</b>		
Interest expense on lease liability	22.42	19.47
<b>Total</b>	<b>144.57</b>	<b>150.86</b>

iv. Amount recognised in statement of cash flows:

Particulars	(Rs. in Lakhs)	
	For the year ended 31st March 2025	For the year ended 31st March 2024
Cash outflow for short-term leases	39.13	41.59
Principal component of cash outflow for lease liabilities	76.68	87.75
Interest component of cash outflow for lease liabilities	22.42	19.47
<b>Total cash outflow for leases</b>	<b>138.23</b>	<b>148.81</b>

v. Movement of Lease Liabilities

Particulars	Mar-25	Mar-24
Opening balance of lease liability	203.80	231.36
Addition to lease liability	258.59	82.02
Interest on lease liability	22.42	19.47
Termination of lease liability	(5.15)	(21.83)
Repayment of lease liability	(99.10)	(107.22)
<b>Closing lease liability</b>	<b>380.57</b>	<b>203.80</b>

3.43: No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.



**CACHET PHARMACEUTICALS PRIVATE LIMITED**  
**NOTE - 3: NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025**

**3.44 Ratio Analysis and its elements**

Ratios	Numerator	Denominator	31-Mar-25	31-Mar-24	% Change	Comments where the difference is more than 25%
1. Current Ratio	Current Assets	Current Liabilities	1.49	1.37	8.7%	-
2. Debt - Equity Ratio	Total Debt	Shareholder's Equity	0.06	0.10	-33.4%	Due to Increase in Net profit after tax
3. Debt Service Coverage Ratio	Earnings available for debt service = (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets etc.)	Interest + Principal repayment	78.65	25.79	205.0%	Due to Increase in Net profit after tax and repayment of loan liabilities in previous year
4. Return on Equity Ratio	Net Profits after taxes - Preference Dividend	Average Shareholder's Equity	41.49%	10.46%	296.6%	Due to Increase in Net profit after tax
5. Inventory Turnover Ratio	Net Sales	Average Inventory	19.29	16.52	16.8%	-
6. Trade Receivables T/o Ratio	Net Credit Sales	Average Trade Receivables	7.81	7.99	-2.3%	-
7. Trade Payables T/o Ratio	Net Credit Purchases	Average Trade Payables	3.91	4.43	-11.7%	-
8. Net Capital T/o Ratio	Net Sales	Working Capital (current assets - current liabilities)	7.96	9.20	-13.4%	-
9. Net Profit Ratio	Net Profit	Net Sales	9.41%	1.87%	402.2%	Due to increase in Net profit after tax
10. Return on Capital Employed	Earnings before Interest and Tax (EBIT)	Capital Employed (Share holder's equity + Total Debt + Deferred Tax Liability)	44.85%	33.85%	32.5%	Due to increase in profit before tax
11. Return on Investments	Income	Investments	7.63%	7.20%	5.9%	-





**Note 3.45 Recent accounting pronouncements**

The Ministry of Corporate Affairs (MCA), vide notification dated 7th May 2025, has issued the Companies (Indian Accounting Standards) Amendment Rules, 2025, introducing an amendment to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates. The amendment provides additional guidance on determining the exchange rate when multiple rates exist and assessing currency exchangeability.


The amendment is applicable for accounting periods beginning on or after the date of its publication in the Official Gazette, and accordingly, will be effective from the financial year commencing 1st April 2025 (FY 2025-26). The Company has evaluated the potential impact of the amendment and assessed that it will not have any material impact on its financial statements.

As per our Report attached of even date,

**For R. S. SANGHAI & ASSOCIATES**

Chartered Accountants

Firm Reg No: 109094W



**R.S.Sanghai**

Partner

Membership No: 036931

Place: Mumbai

Date: 23rd May, 2025



For & on behalf of the Board,

**CACHET PHARMACEUTICALS PRIVATE LIMITED**

CIN:U24230BR1978PTC001328



**S.K.Singh**

Managing Director

DIN : 00245703



**Arunkumar Deshmukh**

Independent Director

DIN : 07210367



**CACHET PHARMACEUTICALS PVT. LTD.**

Regd. Off.: Exhibition Road, P. S. Gandhi Maidan, Patna-800001, Bihar

CIN No.: U24230BR1978PTC001328

Tel. Nos.: 0612-2322570/ 2322588.

Website: [www.cachetindia.com](http://www.cachetindia.com)